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ABSTRACT 
FREESURFER VS MANUAL TRACING: DETECTING FUTURE  
COGNITIVE DECLINE IN HEALTHY OLDER ADULTS  
AT-RISK FOR ALZHEIMER’S DISEASE 
 
 
Alissa M. Butts, M.S. 
 
Marquette University, 2013 
 
 
 Alzheimer’s disease (AD) is a neurodegenerative pathological process that is 
thought to begin years prior to observable symptom onset. The hippocampus appears to 
be particularly vulnerable to the underlying brain pathology of AD. Hippocampal volume 
is a sensitive measure in predicting conversion from mild cognitive impairment to AD, 
but less is known regarding the use of hippocampal volume in asymptomatic individuals 
at risk for AD who eventually decline. The inconsistent findings may, in part, be due to 
the chosen method of hippocampal segmentation. FreeSurfer (FS) and manual tracings 
(MT) are two common segmentation techniques that have unique costs and benefits. The 
present study directly compared hippocampal volumes generated by FS and MT in a 
longitudinal design assessing cognitively healthy elders, with varying degree of risk for 
AD, over a 4.5-year period. After 4.5 years, 15 participants demonstrated cognitive 
decline, while 45 remained stable.  The results suggest FS consistently produced larger 
hippocampal volumes than MT, but neither method distinguished between groups at 
baseline. Longitudinally, individuals who declined experienced a more progressive 
pattern of atrophy compared to those who remained stable. These data suggest that 
hippocampal volume over time may be a useful variable in determining cognitive change 
over time, with the addition of other known risk factors, such as genetic risk. This study 
also suggests that in presymptomatic individuals, MT may not provide added benefit over 
the use of the more cost-effective FS.  
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FreeSurfer vs Manual Tracing: Detecting Future Cognitive Decline 
in Healthy Older Adults At-Risk for Alzheimer’s Disease 
 
 
Alzheimer’s disease (AD) is a growing public health concern that alters the 
quality of life of the affected individual and the individual’s family.  There is a need to 
identify individuals who are at risk for disease development before they demonstrate 
clinical symptoms because there is no current cure or treatment for AD that substantively 
slows disease progression. Indeed, redefined diagnostic criteria, set forth by the National 
Institute on Aging and the Alzheimer’s Association, encourage the exploration toward 
identifying the earliest markers of AD development, with much promise being 
demonstrated by certain neuroimaging techniques, such as structural MRI (McKhann et 
al., 2011). However, limitations such as ambiguous clinical cutoffs and the lack of agreed 
upon routine standards for measurements prevent acceptance of these tools in the clinical 
setting (Jack, Albert, et al., 2011). Demonstration of the predictive clinical utility and 
agreement regarding standard methods in research settings may provide the scientific 
foundations necessary for the application of biomarkers in the clinical setting. Ideally, in 
vivo markers will be established that are sensitive enough to clinically predict future 
cognitive decline in seemingly healthy individuals. 
Reliable, early distinction between those who will eventually develop AD from 
those who will only experience the milder cognitive changes associated with aging, will 
require identification of subtle differences in key brain regions affected at the earliest 
stages of the underlying brain disease. At the earliest stages, this degeneration is most 
apparent in medial temporal lobe (MTL) structures and in particular, the hippocampus. 
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Longitudinal, noninvasive neuroimaging techniques have shown that relative to healthy 
aging, hippocampal volume declines at an increased rate in AD (Costafreda et al., 2011). 
Reductions in hippocampal volume have even been shown in mild cognitive impairment 
(MCI) (Woodard et al., 2009), which is often a prodromal stage of AD (Petersen, 2004). 
Fewer studies involving hippocampal volume and magnitude of change have investigated 
conversion from cognitively healthy to cognitive decline, and fewer still have directly 
compared the methods used to characterize hippocampal volumes. Automated methods 
are cost-effective, but manually derived volumes are the ‘gold standard’ due to the 
afforded precision (Jack, Barkhof, et al., 2011) and the limitations of early automated 
methods. The volume differences and magnitude of atrophy change over time may be 
subtle, if indeed present, in individuals who eventually decline relative to those who do 
not decline. Thus, subtle and accurate in vivo hippocampal measures may be a key 
biomarker used to identify individuals who will develop AD, and thus, who would likely 
benefit most from early intervention.  
Prevalence, Incidence, and Public Health Implications of AD 
 
 
The high prevalence and incidence rates of Alzheimer’s disease is a growing 
public health concern and is creating a large financial burden for caregivers and society. 
An estimated 200,000 people under the age of 65 ("2011 Alzheimer's disease facts and 
figures," 2011) and 5.4 million people over the age of 65 (Hebert, Scherr, Bienias, 
Bennett, & Evans, 2003) are living with AD. By 2050, the number of AD cases is 
expected to triple to between 11-16 million (Hebert et al., 2003). AD is the fifth leading 
cause of death in individuals over the age of 65 (Minino, Arias, Kochanek, Murphy, & 
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Smith, 2002) and is the only disease within the top 10 leadings causes of death without a 
current treatment to cure, reverse, or reliably slow the disease progression ("2011 
Alzheimer's disease facts and figures," 2011). The estimated cost of caring for individuals 
with dementia was estimated at $183 billion in 2011 and is estimated to rise to $1.1 
trillion by 2050 ("2011 Alzheimer's disease facts and figures," 2011). However, if the 
onset of this disease could be delayed by 5 years, the prevalence rate may decrease by 
50%, and a 10-year delay in symptom onset may virtually eliminate AD (DeKosky & 
Marek, 2003).  Delaying AD symptom onset is possible if clinicians can provide an early 
intervention to individuals with underlying AD pathology before symptoms emerge. 
During the “asymptomatic, preclinical phase” of AD, the afflicted have 
pathophysiological disease markers, but still appear cognitively healthy (Sperling et al., 
2011).  It is likely that an AD intervention would be more effective in this earliest, 
presymptomatic stage of the disease. Yet, the ability to differentiate cognitively healthy 
elders who are able to withstand the disease burden from those who are not, and 
eventually become symptomatic remains elusive. An advanced understanding of the 
additive implications of various risk factors for AD development, and their impact on the 
individual over time, might lead to the identification of specific characteristics, or 
biomarkers, that will reliably predict who will eventually develop AD.   
Predominant Risk Factors for Alzheimer’s Disease 
 
 
During the asymptomatic, preclinical phase of Alzheimer’s disease, the individual 
is presumed to have risk factors that increase the likelihood of eventual decline. It is 
possible that understanding and exploring the individual and additive contributions of 
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risk factors such as, demographic characteristics, including age and sex, genetic 
components, and a pre-dementia diagnosis, will lead to the development of a profile of 
characteristic that identify who will later decline into the clinical phases of AD. There are 
many other implicated ‘risk factors’ for AD that affect the individual at the community or 
societal level, such as education and socioeconomic status (Sattler, Toro, Schonknecht, & 
Schroder, 2012); however, for the purposes of this specific study the discussion will 
focus more on biological factors. Although there is no single characteristic that 
determines the absolute development of AD, there is increasing evidence to suggest that 
certain factors dramatically increase one’s risk. 
Age. 
 
 
The neurodegenerative nature of AD results in the emergence of symptoms 
typically after the fifth decade, and as one grows older the likelihood of developing AD 
increases dramatically. Of the cohort of Americans over the age of 65, one in eight (13%) 
will have AD, whereas nearly one in two (43%) Americans over the age of 85 will have 
AD (Hebert et al., 2003). Of the total number of individuals with AD, approximately 4% 
are under the age of 65 years (early onset), 6% are between the ages of 65-74 years, 45% 
are between the ages of 75-84 years, and 45% are 85 years or older ("2011 Alzheimer's 
disease facts and figures," 2011). Roughly, the prevalence rate of AD doubles with every 
five years of age over the age of 65 (Musicco, 2009). Insult or injury from a vascular 
event, diabetes, head trauma, accumulated distress from stressful life events, or risk due 
to genetic factors may each cause the brain to be more vulnerable to the changes that 
occur at the microbiological level (Herrup, 2010). Therefore, the longer the individual 
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lives, the more likely it is that he or she will experience enough insult or injury to deplete 
their individual cognitive reserve (Herrup, 2010) and begin to manifest the clinical 
symptoms of AD. 
Sex. 
 
 
The uneven distribution of AD prevalence rates across sex suggests that the AD 
process differentially affects men and women through a currently unknown mechanism. 
Of the 5.2 million individuals living with AD, 3.4 million are women, whereas 1.8 
million are men ("2011 Alzheimer's disease facts and figures," 2011). European studies 
consistently find higher incidence rates of AD in women compared to men, with women 
being 1.6 times as likely to develop AD than men (Gao, Hendrie, Hall, & Hui, 1998). 
This is consistent with the higher incidence of AD in women in American based samples 
(Vina & Lloret, 2010). A woman’s lifetime risk of developing AD is nearly one in five 
(17.2%), though it is approximately one in ten (9.1%) for men (Seshadri, 2006).  
The leading hypothesis as to why more women tend to develop AD than men is 
because the life expectancy of females is longer than their male counterparts (Vina & 
Lloret, 2010). Alternatively, a study conducted with Italian women found more 
pregnancies in women with AD compared to healthy elders, suggesting that a high level 
of estrogen is a potential contributor to AD development (Colucci et al., 2006). One study 
demonstrated greater metabolism reduction in AD targeted brain regions in women 
relative to men, suggesting women may have reduced cognitive reserve relative to men 
(Perneczky, Drzezga, Diehl-Schmid, Li, & Kurz, 2007). These differences remained even 
after controlling for disease severity, age, and education, placing them at a greater risk of 
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cognitive decline (Perneczky et al., 2007). To date, there is not an agreed upon rationale 
for why there is a discrepancy in prevalence rates in AD across sex. Given that increased 
age is a clear risk factor for AD and women tend to live longer than men, it is possible 
that certain characteristics of women lead to their increased prevalence rate of AD. For 
example, while education may increase cognitive reserve, women historically have had 
fewer educational opportunities than men, and high estrogen levels due to multiple 
pregnancies are unique to women, both of which may contribute to the higher prevalence 
rates of AD in women relative to men.   
Genetics.  
 
 
Although no singular factor has been found to definitively lead to a diagnosis of 
AD, it is believed to be a disease with strong genetic contributions. Individuals with a 
positive family history, as defined as report of AD in a parent or sibling, are more likely 
to develop AD than those without a family history of AD (Green et al., 2002). 
Additionally, the risk of developing AD by 85 years old is about 43.7% for African 
American individuals and about 27% for Caucasian individuals (Green et al., 2002). 
Caucasian females with a first-degree relative with AD are more likely (31.2%) to 
develop AD than their male counterparts (20.4%). African American females with a first-
degree relative with AD are no more likely (46.7%) to develop AD compared to their 
male counterparts (40.1%), though an increased likelihood is trending toward 
significance (Green et al., 2002). These statistics suggest at least a partial biological 
component to AD, in that sex and ethnicity are uniquely informative and interact with a 
positive family history to increase an individual’s risk of developing AD.  
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In addition to a positive family history of AD, the impact of a number of genes 
and proteins on an individual’s likelihood of developing AD has been explored. In 
particular, four genetic markers have received specific investigation in studies of the risk 
for late-onset AD (i.e., the most common form of AD): a) the Translocase of Outer 
Mitochondrial Membrane-40 homolog (TOMM40) gene, via the length of its 
polymorphic poly-T variant, rs10524523, connecting TOMM40 to the APOE gene 
(Roses et al., 2009); b) the β–amyloid precursor protein (β-APP), associated with 
mitochondrial dysfunction (Corder et al., 1993); c) mutations of the presenilin-1 (PSEN1) 
or presenilin-2 (PSEN2) proteins, which may contribute to Aβ accumulation in the 
extracellular space (Strittmatter et al., 1993); and d) apolipoprotein-E (APOE) ε4, which 
has to date shown by far the strongest association with AD development. By virtue of its 
predictive ability, APOE will be the only gene further discussed in this paper. 
APOE is polymorphic biochemically and has three different allele forms: ε2, ε3, 
and ε4. Every individual carries two alleles in some combination of the three forms.  
While all combinations are known to occur, ε3ε3 occurs most commonly in the general 
population (68%) (Corrada, Paganini-Hill, Berlau, & Kawas, 2012), while ε2ε2 is the 
most rare (<1%) (Hyman et al., 1996). The ε4 allele has been shown to confer the greatest 
risk of developing AD, while ε2 may confer some protection (Martins, Oulhaj, de Jager, 
& Williams, 2005). Although carrying the ε4 allele does not mean that an individual will 
develop AD, the risk of AD development increases from 20%, for individuals who carry 
no ε4 allele, to 46.6% for individuals with one ε4 allele (heterozygous), and to 90% for 
individuals with both ε4 alleles (homozygous) (Corder et al., 1993). The ε2/ε4 
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combination is found in 2% of the general population, ε3ε4 in 15%, and ε4ε4 is found in 
<1% of the population (Corrada et al., 2012).   
The effects and importance of APOE ε4 can be readily seen when examining the 
age of onset of AD and the general odds ratios, or all-cause probability of developing 
AD. The age of AD onset, based on examination, was shown to be reduced to 68 years on 
average when carrying two ε4 alleles compared to an average age of onset of 84 years in 
non-carriers (Corder et al., 1993). Moreover, it has been estimated that nearly all 
individuals homozygous for the ε4 allele will develop AD by the age of 80 (Corder et al., 
1993), and will experience a faster rate of decline relative to non-carriers (Martins et al., 
2005). In addition, the risk of AD with ε4 may be greater for women: Bretsky et al. 
(1999) found that women, but not men, with at least one copy of the ε4 allele were 7.8 
times more likely to develop AD than women without the ε4 allele. The odds ratio (OR) 
of developing AD for non-carriers of ε4 (i.e., ε2/ε2, ε2/ε3, or ε3ε3 genotypes) is 0.6, yet 
it is 2.6 for the ε2/ε4 genotype, 3.2 for the ε3/ε4 genotype (Saunders et al., 1993), and is 
14.9 if the individual is homozygous (ε4/ε4) for the APOE ε4 allele (Farrer et al., 1997).   
Although the ε4 allele appears to be a strong indicator of AD development, APOE 
status alone cannot predict who will definitively develop AD, or even who will manifest 
clinical symptoms. As such, because genetics provide a strong predictive foundation, 
genetic risk factors in addition to other known risk factors, may provide a more exact 
indicator of cognitive decline. 
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Mild Cognitive Impairment. 
 
 
One of the greatest risk factors for AD is a clinical diagnosis of mild cognitive 
impairment (MCI). The general term of MCI refers to a state of functioning in which an 
individual has some degree of cognitive impairment relative to healthy aging, but is not 
severe enough to meet diagnostic criteria for dementia (Petersen et al., 2001). Thus, MCI 
is often considered to be a transitional stage between healthy aging and AD because this 
diagnosis marks the initiation of symptom onset. The following discussion explains what 
is expected of memory change over time in healthy aging, how that differs in MCI and 
AD, and how that can be applied to detecting the earliest risk for AD.  
Hippocampus and Memory in Aging, MCI, and AD 
 
 
Alzheimer’s disease is a progressive neurodegenerative disorder with a distinct 
clinical presentation of cognitive deficits and corresponding neuropathological 
characteristics that create a profile of changes far exceeding those that occur as a part of 
healthy aging. This decline is gradual over time but it reflects a marked reduction from 
the individual’s previous level of functioning (APA, 2000). In particular, episodic 
memory in AD appears to represent the most dramatic and earliest change in memory, 
and in cognition in general (Dubois et al., 2007), which correlates to the earliest neural 
changes occurring in the MTL (Braak & Braak, 1991). The hippocampus, which is 
essential for memory, within the MTL appears to be asymmetrical as a part of normal 
aging, which may contribute its vulnerability in disease states. Better understanding of 
the pattern of memory change over time in normal aging and AD, and the integrity of 
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associated supporting anatomical regions, may help to inform which feature(s) might be 
most indicative of insidious cognitive decline in cognitively intact individuals. 
Volume differences between the left and right hippocampi across many age 
groups have been well documented, wherein there is a right greater than left tendency 
(Giedd et al., 1996; Honeycutt & Smith, 1995; Wolf et al., 2001).  The etiology of this 
asymmetry is unknown, yet it is possible that it has evolutionary meaning. That is, the 
right hippocampus has been linked to spatial navigation and memory, and the left 
hippocampus has been linked to more verbally mediated memory processes (Kilpatrick et 
al., 1997).  It may be that humans relied more on spatial navigation skills throughout 
development, giving rise to larger baseline right hippocampi that have continued to be 
observed in more recent neuroimaging studies. Asymmetrical differences have been 
documented even in children and adolescents. One study examining the hippocampus in 
individuals between the ages of 4- to 18- years old found that the hippocampus, 
bilaterally, increased with age and that the right hippocampus was larger than the left 
hippocampus (Giedd et al., 1996). This pattern of asymmetry, wherein the right 
hippocampus is shown to be larger than the left hippocampus, has been consistently 
documented in healthy young adults (Honeycutt & Smith, 1995), as well as older adults 
(Wolf et al., 2001). Further volume reductions, or atrophy, of the left hippocampus as a 
result of a disease process has been shown to be strongly correlated with poorer memory 
performances, particularly for verbal memory tests (Kilpatrick et al., 1997). Some studies 
have documented even smaller baseline left hippocampal volumes in individuals who 
eventually convert to dementia compared those who remain stable (Fox et al., 1996). As 
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such, the asymmetry of the hippocampus may lead some individuals to be more 
vulnerable to disease insults, and as such, may be a useful indicator of detecting future 
cognitive decline. 
In normal aging, various cognitive skills change over time to different degrees 
and at different rates. That is, certain skills demonstrate a more significant change, while 
others may change more subtly, and some may decline earlier while others may be more 
stable. Memory in particular, is a cognitive domain that is variably affected by the aging 
process, and is drastically affected in AD. Semantic memory, also known as ‘knowledge’ 
or memory for factual information, appears to be relatively preserved in healthy aging 
(Hoff, 2009).  In contrast, episodic memory, or memory for information with temporal 
and/or personal relevance, tends to decline more with age than semantic memory (Grady 
& Craik, 2000). Functional neuroimaging studies reveal an increase in neuronal activity 
in memory-facilitating structures, such as the hippocampus, in healthy older adults 
relative to younger individuals (Nielson et al., 2006). This pattern of increased neuronal 
activity, which has been shown in numerous studies using various tasks (e.g., (Cabeza & 
Nyberg, 1997; Grady & Craik, 2000; Grady, McIntosh, & Craik, 2005; Langenecker & 
Nielson, 2003; Nielson et al., 2006; Nielson, Langenecker, & Garavan, 2002; Woodard et 
al., 2010), has most often been explained as neural compensation or ‘recruitment.’ That 
is, data from these studies suggest that as the brain ages, it ‘recruits’ additional neural 
activation to support performance during cognitive demand (Nielson et al., 2006).  
In contrast to the typical cognitive changes associated with aging, individuals with 
MCI show a change in cognition beyond what is expected to occur with normal aging. 
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MCI has been recently re-categorized as within the “symptomatic, pre-dementia phase” 
(Albert et al., 2011). It is thought to be a transitional state between healthy aging and 
dementia. Indeed, 12% of patients diagnosed with MCI convert to dementia each year, 
with 31% to 44% of the converters progressing eventually to AD (Busse, Hensel, Guhne, 
Angermeyer, & Riedel-Heller, 2006). The individuals who decline from MCI to AD tend 
to be those with prominent memory disturbance, relative to other cognitive skills 
(Petersen, 2004). In contrast, only 1-2% of the general population is thought to convert 
from cognitively intact to dementia in a one-year interval (Petersen & Morris, 2003). Part 
of the high MCI conversion rate may be due to underlying neural changes that are 
occurring as part of the AD trajectory. Specifically, the functional recruitment, or 
hyperactivation, in the hippocampus seen in healthy aging is even more pronounced 
during memory tasks in those with MCI, suggesting that the brain is attempting to 
compensate for the disease process (Woodard et al., 2009). Yet, as MCI progresses to 
AD, as evidenced by increased deterioration of episodic memory skills and additional 
cognitive deficits (Dubois et al., 2007), the brain cannot compensate for the disease 
process, and the functional hippocampal activation in AD then drops off to less than that 
of healthy controls (Celone et al., 2006; Dickerson et al., 2005). Therefore, the ability to 
accurately diagnose MCI and understand its conversion to AD, while important, is likely 
too late in the disease process to intervene to an impactful degree because at this point of 
symptom onset, neuropathological change has already occurred and the current 
medications only potentially provide brief management of symptoms (Hong-Qi, Zhi-Kun, 
& Sheng-Di, 2012).  
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It may be beneficial to use the functional and cognitive characteristics of healthy 
aging and diseased aging (i.e. MCI and AD) as a gauge to help determine what factors 
may be suggestive of an individual who is at risk for cognitive decline. Importantly, 
although individuals who are at risk for AD perform similarly on cognitive tasks to those 
not at risk, they exhibit hippocampal hyperactivation that is comparable to those with 
MCI (Bondi, Houston, Eyler, & Brown, 2005; Seidenberg et al., 2009). The increased 
recruitment seen in those at risk for AD, suggests that not all “cognitively intact” 
individuals are on the trajectory of normal aging. Instead, these data indicate the presence 
of early degeneration affecting the function, and likely the structure, of the hippocampus. 
Thus, interventions have the most potential for efficacy during this pre-symptomatic 
stage, because of the early stage of disease progression. Examining asymptomatic 
individuals at risk for developing AD and following them over time will allow for an 
observation of change over time as many develop MCI, and some develop AD. More, 
studying these asymptomatic individuals before symptoms emerge might allow for the 
discovery of predictors for the development of MCI and AD. 
Structural Effects on Hippocampus in the AD Course  
 
 
Following the trajectory of an individual’s memory ability via neuropsychological 
testing is certainly useful; it can clearly delineate change over time and may eventually be 
used to indicate symptom onset. Yet, it is well understood that the neuropathological 
changes underlying AD begin long before symptoms are measurable with 
neuropsychological testing (Morris, 2005).  Therefore, accurate early identification of 
neuropathological changes in at-risk elders is essential to advancing the treatment or 
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prevention of AD. Unfortunately, at the earliest stage of disease development individuals 
at risk for developing AD may perform cognitively within their expected performance 
range, when underlying brain changes suggest a disease trajectory. That is, 
neuropsychological tests effectively evaluate overt cognitive functioning, but there may 
be times in which information regarding the covert integrity of the brain will provide 
additional evidence that an individual is likely to decline. 
At the molecular level, the pathological process of AD includes many 
histopathological changes in the brain prior to and following symptom onset. In fact, the 
underlying neurodegenerative process of AD is thought to begin decades before the onset 
of clinical symptoms (Morris, 2005). Histologically, AD is differentiated from other 
dementias by the presence of intracellular neurofibrillary tangles and extracellular beta-
amyloid plaques (Jellinger, Danielczyk, Fischer, & Gabriel, 1990). It is the presence, 
location, and the effects of these signature proteins that likely contribute to the cognitive 
deficits associated with AD. 
Beta-amyloid is a normally occurring protein in the brain; however, in AD over-
productivity or insufficient disposal of this protein results in aggregation and progressive 
deposition, which leads to the conglomeration of plaques (Petrella, Coleman, & 
Doraiswamy, 2003). The beta-amyloid accumulation is thought to begin early in the 
pathogenesis of AD and leads to additional insults to the brain, such as local 
inflammatory changes, neurofibrillary degeneration, and neurotransmitter deficits in 
memory facilitating structures (Walsh & Selkoe, 2004). Plaques and tangles associated 
with AD pathology have been found to first arise in the entorhinal cortex of the MTL, 
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then to spread to the adjacent hippocampus of the MTL, and finally to proliferate into the 
neocortex (Braak & Braak, 1991). This pattern of plaque and tangle emergence in the 
MTL is consistent with the earliest clinical symptom of marked and progressive 
impairment in the acquisition of episodic memories, for which, MTL structures play an 
important role.   
In addition to the plaques and tangles, synaptic loss is thought to be a contributing 
factor to the clinical deficits observed in individuals with AD pathology (Arendt, 2009), 
with the hippocampus appearing to be particularly vulnerable to synaptic loss (Scheff, 
Price, Schmitt, DeKosky, & Mufson, 2007). The accumulated loss of individual synapses 
over time is thought to give rise to eventual loss of grey matter (Kassem et al., 2012). 
Indeed, the overall volume loss that occurs in AD is greater than that which is observed 
as a part of healthy aging (Juottonen, Laakso, Partanen, & Soininen, 1999), with 
approximately 12.2% lower total gray matter volume in individuals with AD relative to 
cognitively healthy elders (Karas et al., 2004). Fjell et al. (2009) examined the brain 
volumes of healthy older individuals over multiple time points and found that atrophy 
occurred at the rate of approximately 0.5% per year in the temporal and prefrontal 
cortices (PFC), two regions involved in memory performance. The negative correlation 
between age and volume was strongest for the entorhinal cortex and bilateral 
hippocampus, such that the older an individual, the smaller the volume of the MTL (Fjell 
et al., 2009).  The hippocampus in particular has been shown to be 12% smaller in 
individuals with AD compared to non-demented elders, with similar reductions in the left 
and right hippocampus (Scher et al., 2007). Structural changes (e.g. medial temporal lobe 
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atrophy) presumably due to AD pathology are notable in the pre-dementia stage of MCI. 
Relative to other cortical regions, entorhinal cortex thickness and the volume of the 
bilateral hippocampus have been shown to be the most sensitive structural differences in 
differentiating MCI and healthy controls (Desikan et al., 2010).  Indeed, individuals with 
MCI have been documented as having smaller hippocampal volumes than healthy 
controls, with a particularly smaller left hippocampus and a trending toward significantly 
smaller right hippocampus (Woodard et al., 2010). These cross-sectional studies highlight 
the change in hippocampal volume in individuals with MCI and AD as a result of the AD 
process.   
In addition to the cross-sectional volume differences that have been observed 
throughout the course of AD pathology, the rate of atrophy in AD-targeted regions over 
time in longitudinal paradigms has been documented and used to explore potential 
prediction models of cognitive decline. In one study examining the unique contribution of 
regions within the MTL, found that individuals with smaller entorhinal cortex, but not 
hippocampus after controlling for the entorhinal cortex, were more likely to convert to 
AD (Stoub et al., 2005).  In this sample of 58 nondemented individuals, 14 converted to 
AD and 11 of those converters met criteria for MCI at baseline. This finding may imply 
that entorhinal cortex atrophy is more indicative of future decline than the hippocampus. 
However, remarkably, the rate of hippocampal volume loss bilaterally has been shown to 
be more rapid (1.18% per year) than entorhinal cortex atrophy (0.53% per year) in 
healthy older adults over time (Raz, Rodrigue, Head, Kennedy, & Acker, 2004). In AD, 
the rate of bilateral hippocampal atrophy has been shown to be approximately twice the 
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rate observed in healthy aging (Jack et al., 1998). Furthermore, in a study comparing 
MTL regions over time, both entorhinal cortex and hippocampal atrophy had large effect 
sizes in comparing converters and nonconverters, but the hippocampal effect size was 
larger than that of the entorhinal cortex (Desikan et al., 2008). Additionally, other 
conversion studies have identified the hippocampus as a greater indicator of future 
decline. For example, one conversion study examining parahippocampal gyrus volume, 
including the entorhinal cortex, and hippocampus found hippocampal volume to be a 
better predictor of MCI to AD conversion than non-hippocampal structures, such as the 
entorhinal cortex (Visser, Verhey, Hofman, Scheltens, & Jolles, 2002).  A final study 
found baseline hippocampal volume and rate of atrophy bilaterally provided greater 
predictability in MCI to AD conversion than other regions (Henneman et al., 2009).  
Together, these studies highlight the importance of medial temporal lobe atrophy in 
predicting cognitive decline, with somewhat inconclusive results as to whether a single 
MTL structure is uniquely reliable in predicting decline. Still, hippocampal atrophy has 
been shown to be one of the most important structures in identifying individuals who 
decline over time from MCI to AD. Needed, are more studies that assess the utility of 
cross-sectional and longitudinal hippocampal measurements in predicting decline in 
cognitively intact elders at risk for AD who eventually convert.   
Consistent with the notion that the pathological processes of AD begin years 
before cognitive deficits are notable (Morris, 2005), it is possible that the AD-related 
morphological changes may extend to the asymptomatic, preclinical phase, when the 
individual is still cognitively intact yet is at risk for AD development.  There appear to be 
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inconsistent findings in the literature regarding the presence of hippocampal differences 
in those at risk compared to not at risk. For example, one study observed smaller volumes 
bilaterally in asymptomatic women at risk for developing AD relative to those not at risk 
(Cohen, Small, Lalonde, Friz, & Sunderland, 2001). In contrast, Burggren et al. (2008) 
found comparable hippocampi in cognitively healthy individuals at risk compared to 
those not at risk. Part of the inconsistencies between these studies may be due to the 
methods that were used to measure hippocampal volume and change over time. For 
example, the method used to measure hippocampal volume in Burggren et al. was 
different from the method used in Cohen et al. and therefore may account for the different 
findings. Instead of using complete manual derivations of the hippocampus, as was done 
in the Cohen et al. study, Burggren et al. began by manually separating the white matter 
of the MTL from the cerebral spinal fluid (CSF) and then used an automated cortical 
unfolding method to further define MTL subregions, including those of the hippocampus 
(Burggren et al., 2008). Using this approach, essentially utilizing automated techniques to 
label hippocampal tissue, they did not find group differences in hippocampal volume 
between groups (Burggren et al., 2008). In contrast, Cohen et al. used fully manualized 
methods to define hippocampal volume, and did find differences between groups (Cohen 
et al., 2001). The discrepant findings in these two studies suggest that, cross-sectionally, 
hippocampal volume differences between those at high risk compared to low risk, if 
present, may be subtle. Observing the pattern of hippocampal atrophy over time may also 
be useful in identifying indicators of future cognitive decline. 
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Few studies have been conducted that follow cognitively intact individuals 
longitudinally and explore the role of the hippocampus in conversion over time. An older 
study using serial MRI measurements, with manual tracings, found that healthy 
participants who later decline had smaller baseline hippocampi relative to healthy 
participants who remained stable (Kaye et al., 1997). Yet, the participants in the Kaye et 
al. study were at least 84 years old at study entry, and those who declined were older and 
had poorer cognitive performance to begin the study than those who remained stable. 
Therefore, it may be possible that a different disease process was detected in that study. 
In a more recent longitudinal study, larger manually derived total hippocampal volumes 
in cognitively intact elders at risk for AD were shown to be protective against cognitive 
decline after an 18-month interval (Woodard et al., 2010). These studies suggest that 
there may be subtle quantifiable differences in brain structure between cognitively 
healthy individuals at risk for AD who eventually decline and cognitively healthy 
individuals who remain stable over time. Yet, Jak et al. (2007) did not find a difference in 
baseline total hippocampal volume between risk groups; however, they did find a greater 
rate of atrophy measured longitudinally in those at risk relative to those not at risk, using 
manual methods (Jak, Houston, Nagel, Corey-Bloom, & Bondi, 2007). This study also 
did not find hippocampal volume to be significantly related to relative cognitive decline 
over time, although declining and stable participants were mixed amongst the risk groups 
(Jak et al., 2007), which may have contributed to the lack of significant correlation with 
the hippocampal volumes. Notably, the goal of their study was to examine the impact of 
risk status on hippocampal volume over time. Given that no single risk factor has been 
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shown to be 100% predictive of AD development, it would be valuable to observe 
hippocampal volume change over time in cognitively healthy individuals who eventually 
convert.  
To summarize, a number of studies have shown subtle hippocampal volume 
differences at various time points in cognitively intact individuals who are at risk for AD. 
In addition, some studies have suggested that the rate of change over time in hippocampal 
volume differs in those at higher risk compared with those at lower risk, whereas others 
have not supported these findings. Some of the inconsistencies may be due to the 
variability in the methods used across studies with this population. As such, clear group 
definition and structure inclusion may help to clarify potential group differences. That is, 
because these differences may be subtle, structural MRI studies that seek to be sensitive 
to the slight hippocampal volume differences in individuals who eventually decline may 
require careful awareness of the boundaries of surrounding structures and account for the 
possibility of ‘partial voluming’, or the inclusion of tissue from adjacent brain regions 
that are not targeted for inclusion. As such, a method with exceptional refinement 
capabilities may be warranted to assess for possible hippocampal volume differences at 
the earliest stage of AD. Therefore, a direct comparison in longitudinal data of two 
commonly used methods of isolating hippocampal tissue would be valuable toward 
helping to identify the most sensitive approach to discern early, subtle, hippocampal 
differences between AD risk groups.  
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Rationale for Present Study: FreeSurfer vs. Manual Hippocampal Volume 
Measurement. 
 
 
Clinical classification studies that involve determining volume differences in 
specific brain structures employ either automated methods, such as FreeSurfer, or 
manually defined regions of interest, both of which are accompanied by specific costs 
and benefits. FreeSurfer is the predominant automated approach that is used to label 
cortical and subcortical brain structures, and it is compatible with multiple computer 
operating systems as well as functional and structural brain imaging software programs 
(Fischl, 2012). Notably, 20 versions of FS have been released between March 2006 
(Version 3.0.0) and May 2011 (Version 5.1.0). FreeSurfer, which will be described in 
further detail in the methods section, is available for free download 
(http://surfer.nmr.mgh.harvard.edu) and labels regions of interest (ROI) through a series 
of tissue-isolating steps. As such, the use of FreeSurfer requires neuroimaging software 
processing knowledge and training. That is, FS requires running various commands and 
scripts to transform raw scanning data into appropriately processed numerical data 
representing each individual scan. Additional knowledge is then required to prepare the 
data for group comparisons and apply these numerical values to neuroimaging software 
programs such as Analysis of Functional NeuroImaging (AFNI) and Statistical 
Parametric Mapping (SPM). For volumetric studies, once the segmentation scripts are 
completed, the volumes may then need to be transformed into visually represented ROIs 
through the use of programs, such as AFNI or SPM. Although multiple neuroimaging 
processing steps are required, and many steps take multiple hours to execute, once the 
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command begins, it will run independently without the constant attention of the 
researcher.  
In contrast, manual tracings require a greater amount of labor, necessitating the 
constant attention of the researcher to complete the tracing, and are thus more time 
consuming than FreeSurfer (Jack, Barkhof, et al., 2011). Furthermore, manual tracings 
also require that the tracer have neuroanatomical knowledge and training (Jack, Barkhof, 
et al., 2011). Despite these potential costs of resources, tracings may allow for greater 
specificity in isolating voxels that include tissue belonging to relevant structures, and as 
such are considered to be the ‘gold standard’ in deriving hippocampal volume (Jack, 
Barkhof, et al., 2011). Thus, both approaches require neuroimaging and neuroanatomy 
knowledge, but the particular skills, as well as the costs and benefits, vary between 
method. Because FreeSurfer is one of the most commonly used automated methods and 
manual tracings are considered to be the ‘gold standard’ in defining hippocampal volume, 
these two approaches will be the focus of the present paper.  
There are only a small number of studies that directly compare volumes generated 
by FreeSurfer and manual tracings, particularly as they relate to predicting cognitive 
decline. Both FreeSurfer and manual tracings have been shown to accurately differentiate 
clinical populations, such as AD and semantic dementia, from healthy controls (Lehmann 
et al., 2010). One study compared manual tracings to FreeSurfer (Version 4, released in 
August 2007) in participants with MCI, early AD, elders with cognitive complaints but 
normal neuropsychological testing, and healthy elderly controls (Shen et al., 2010). This 
study found manually traced and FreeSurfer volumes were highly correlated to one 
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another and both were able to detect smaller hippocampal volumes in the clinical groups 
(early AD and MCI) relative to the nonclinical groups (healthy controls and elders with 
cognitive complaints but normal neuropsychological testing, CC) (Shen et al., 2010). The 
authors also report that both techniques showed the same pattern of atrophy AD > aMCI 
> CC (Shen et al., 2010). They suggest that the cognitive complaints group may mimic a 
preMCI group, which may lend to the theory that those with impending cognitive decline 
may not show hippocampal volume differences prior to measurable cognitive change. 
However, this study also showed that FreeSurfer yielded larger hippocampal volumes 
relative to the manual tracings, particularly in the hippocampal tail, and included a 
number of small areas that were presumably not hippocampal tissue but were instead 
adjacent MTL regions (Shen et al., 2010), which may have led to an inability to detect 
group differences in the CC group. Additionally, an older version of FS was used, and 
they did not follow the cognitive complaints group over time to determine if they 
eventually demonstrated decline on formal neuropsychological testing.   
In another study with a sample of MCI, AD, and healthy controls, FreeSurfer 
(Version 4.0.2, released in December 2007) hippocampal volumes were compared to 
manually traced hippocampal volumes by evaluating percent overlap, percent volume 
difference, Pearson correlations, and Bland-Altman plots between FS and MT across 
groups (Sanchez-Benavides et al., 2010). This study demonstrated that, similarly to Shen 
et al. (2010), both FreeSurfer and manual tracings revealed a pattern of increasingly 
smaller volumes with an increase in disease severity (healthy controls > MCI > AD) 
(Sanchez-Benavides et al., 2010). Based on the similar pattern of hippocampal volume 
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across groups, the strong correlation between the two measures (Pearson correlation = 
0.84), and the Bland-Altman plots, they concluded that the two methods have 
“acceptable” interchangeability, but they acknowledge that FreeSurfer volumes were 
10% larger on average than manual tracings (Sanchez-Benavides et al., 2010). In this 
study, a direct comparison between the manually traced volumes and FreeSurfer volumes 
revealed a 78% percent overlap between the two methods, but consistently found 
FreeSurfer to yield larger hippocampal volumes than the manual tracings in all 
participant groups (Sanchez-Benavides et al., 2010). The authors caution, that while FS 
may be used in general studies comparing populations, using FS as a primary volumetric 
method may increase the risk of Type II error, particularly in populations with atrophic 
brains, such as those with MCI and AD, or other clinical processes (Sanchez-Benavides 
et al., 2010). 
 The occurrence of FreeSurfer yielding larger volumes has been documented even 
in healthy populations (Cherbuin, Anstey, Reglade-Meslin, & Sachdev, 2009; Morey et 
al., 2009), particularly in the hippocampus (Lehmann et al., 2010). That is, a direct 
comparison between FreeSurfer and manual tracings yielded 23% larger left and 29% 
larger right hippocampal volumes generated by FreeSurfer (Cherbuin et al., 2009). This 
considerable difference in volumes derived from FreeSurfer relative to manual tracings 
was found in a large sample of healthy individuals with well-defined structural 
boundaries. They further demonstrated an even greater volume difference for individuals 
with indications of abnormally structured hippocampi (Cherbuin et al., 2009). This 
difference in methodology suggests that the potential for costly over-inclusion of tissue 
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with FreeSurfer is even more likely when using this method in individuals with less well 
defined structural boundaries, as is likely the case for diseased populations and 
potentially cognitively healthy individuals that are on a disease trajectory.  
For example, some studies have directly compared manual tracings to two 
automated methods, one of which was FreeSurfer, and have found a pattern of over-
inclusion in FreeSurfer volumes, similar to that reported in earlier studies, in individuals 
with Major Depressive Disorder (Morey et al., 2009; Tae, Kim, Lee, Nam, & Kim, 2008). 
More specifically, in one study, FreeSurfer hippocampal volumes were 35% larger than 
manually traced hippocampal volumes in participants with Major Depression, leading the 
authors to conclude that manual tracings are preferable to FreeSurfer (Tae et al., 2008). 
The difference between the methods found in this population (35% larger FreeSurfer 
volumes) was even greater than the difference reported by Cherbuin et al. (2009) (23-
29% larger FreeSurfer volumes) for a healthy population.  
In another study, Morey et al. (2009) compared FS and another automated method 
to manually traced hippocampal volumes in a sample of individuals with depression 
compared to controls. They acknowledge manual tracings to be the standard because it is 
considered to be the closest representation of true hippocampal anatomy (Morey et al., 
2009). The variance associated with FreeSurfer was greater than the manual tracings, but 
the correlation between the manual tracings and FreeSurfer was strong (R = .82), with a 
strong coefficient of determination (r2 = .67), suggesting that 67% of the variance was 
shared by the two methods. Based on the greater variance associated with FreeSurfer, 
they suggest that a slightly larger sample size would be required if FreeSurfer is a utilized 
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method to find the same effect size as manual tracings (Morey et al., 2009). Further, they 
found FreeSurfer to overlap with manual tracings by 82%. The between group 
comparison was also revealing in that they found FreeSurfer hippocampal volumes of 
individuals with depression were 9% smaller compared to controls, with a moderate 
effect size (η2 = .08). They did not report on group differences found by manual tracings 
(Morey et al., 2009). These studies highlight the potential need for precise hippocampal 
measurement particularly in special populations, such as those with underlying disease 
and neurodegenerative pathology. 
In summary, these studies suggest that both manual tracings and FreeSurfer can 
be used to distinguish between clinical groups and healthy controls, although they also 
reveal a pattern of FreeSurfer having a tendency toward producing larger absolute 
volumes. This greater absolute volume difference may not affect group comparisons 
when attempting to distinguish between groups with large volume differences, as may be 
the case when comparing clinical and nonclinical groups. However, attempting to 
distinguish between groups with subtle volume differences may require a greater 
attention to detail and more refined volume measurement capabilities. That is, the ability 
to detect the subtle, if present, differences that may exist between cognitively healthy 
individuals who later decline and those who remain stable may require a method with 
exceptional refinement ability.  
Importantly, a newer version of FreeSurfer (Version 5.1.0, released May 2011) 
incorporates a number of software adjustments to presumably account for the problem of 
voxel over-inclusion. More specifically, this newer version includes GEnerative Model-
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based Segmentation (GEMS) that allows for improved hippocampal definition, as well as 
hippocampal subfield derivations (Van Leemput et al., 2009). While this upgrade may 
improve hippocampal segmentation, it is currently unknown if it has been improved 
enough to distinguish between individuals who eventually decline from those who remain 
stable. As such, a direct comparison of this new FreeSurfer version to manual tracings 
may help inform if one technique has a greater indication for use in detecting individuals 
who eventually decline. 
Although time-intensive in comparison to FreeSurfer, it is possible that the 
additional refinement afforded by the manual editing of the hippocampal volumes may 
still be important in the ability to distinguish between hippocampal volumes of 
cognitively intact individuals who will later demonstrate decline from those who will 
remain stable. If manual tracings reliably provide this necessary refinement, then the cost 
of training and resources may be worth the knowledge gained for treatment planning and 
prognosis. Therefore, if hippocampal volume is an important indicator of future cognitive 
decline in lengthy longitudinal studies, it is important to assess whether the method of 
determining volume influences the sensitivity of such studies. Thus, the present study 
aims to explore the currently unaddressed possibility that FreeSurfer (Version 5.1.0) and 
manual tracings differ in their ability to distinguish between individuals who eventually 
decline from those who remain stable in a sample of cognitively intact elders. 
Our Previous Research Toward Early Detection of AD. 
 
 
To better understand the AD process with the goal of identifying a biomarker for 
AD development, we have been exploring the impact of various biological markers and 
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risk factors for AD. Our population has included older adults who were cognitively intact 
based on neuropsychological testing at study entry 4.5 years ago. Although all of these 
individuals were determined to be cognitively intact, some subsets had specific risks for 
AD, including a positive AD family history and at least one APOE ε4 allele. Each testing 
visit consisted of a neuropsychological battery and an MRI with functional and structural 
acquisitions. Participants were retested at an 18-month and a 4.5-year follow-up session. 
The majority of our work thus far has focused on cross-sectional differences in 
spatial extent and magnitude of activation, during our functional MRI task, in individuals 
at risk relative to other groups (e.g., Seidenberg et al., 2009). We have also begun 
conducting longitudinal analyses in which we can explore factors relevant to cognitive 
change over time. At the 18-month retest, we showed that age, education, sex, and a 
positive family history of dementia failed to adequately predict cognitive decline 
(Woodard et al., 2010). However, several factors did provide significant and independent 
predictive power.  Specifically, smaller baseline hippocampal volume was a valuable and 
independent additive predictor of individuals who declined over the 18-month interval (p 
= .016) (Woodard et al., 2010). Data from the retest 4.5 years beyond baseline have not 
yet been published. The 18-month retest findings highlight the importance of precise 
hippocampal volume measurement to the prediction of cognitive decline (Woodard et al., 
2010), which is somewhat complex and varies by the method used.  
There have been a limited number of preliminary analyses conducted on 
approximately 60 participants who have already undergone the 4.5-year follow-up 
testing. In our previous prediction publication (Woodard et al., 2010), ”decline” was 
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defined as a reduction from baseline performance to 18-month follow-up performance of 
at least one standard deviation on at least one of three principal outcome cognitive indices 
(DRS-2 total score, RAVLT Sum of Trials 1-5, RAVLT Delayed Recall). These 
measures are described in further detail in the methods section. Based on this definition, 
45 of the 60 individuals remained cognitively stable from baseline to the 4.5-year follow-
up, while the remaining 15 individuals exhibited decline. Of the 45 “stable” participants, 
14 were +ε4 (31.1%) and 10 (66.7%) of the “declining” participants were +ε4. In a 
separate 18-month follow-up study not yet published, we showed that individuals who 
decline over 18 months have smaller baseline hippocampal volumes than individuals who 
remain stable over the 18-month interval. We do not yet know, however if this volume 
difference is a harbinger of continued cognitive decline over time at a rate steeper than 
those with larger baseline volumes.  Examining cognitive change over a 4.5-year interval 
in comparison with baseline hippocampal volume is an important next step toward 
understanding the importance of hippocampal volume to predicting cognitive decline and 
its role in risk for AD.  
Goals of the Present Study. 
 
 
As described, few studies examining hippocampal volume have followed 
cognitively healthy individuals over time, and fewer still have attempted to directly 
compare the ability of manual versus FreeSurfer (Version 5.1.0) hippocampal 
segmentation in differentiating future cognitive decline. Therefore, this study will 
specifically compare the ability of automated FreeSurfer hippocampal volumes to the 
ability of manually traced hippocampal volumes to identify individuals who eventually 
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decline in a sample of cognitively intact elders followed over 4.5 years. The following 
hypotheses were tested in the current study: 
Hypothesis 1: Manually traced (MT) baseline hippocampal volumes will more 
optimally differentiate between Stable and Declining participants compared to FreeSurfer 
(FS). This was anticipated because manual tracings allow for more refined hippocampal 
volume measurement than FreeSurfer, which is likely necessary to differentiate between 
the subtle hippocampal volume differences in this asymptomatic – preclinical phase. That 
is, if there are baseline volume differences between cognitively intact individuals who 
eventually decline and stable participants, then it would be expected that MT volumes 
would differ significantly between groups, while FS volumes may not. If the FS volumes 
distinguish significantly between groups, the effect size for that difference was expected 
to be smaller than the effect size for the difference obtained from MT. 
Hypothesis 2: The rate of hippocampal atrophy from baseline to the 4.5-year 
follow-up would differ by method. Manually traced volumes were expected to show a 
greater amount of atrophy between groups compared to the FreeSurfer volumes, such that 
there was an anticipated interaction between methods across the time points between 
groups. That is, at the follow-up assessment the groups were clinically different, as 
determined by group status, and this difference between the groups was expected to be 
large enough such that the greater variance associated with FS would have less of an 
impact on its ability to detect differences. That is, the degree of shared variance and 
overlap between FS and MT reported in previous studies with different clinical groups 
and similar methodology (e.g. Morey et al. 2009), suggests at the follow-up, both 
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methods may accurately differentiate the cognitively different groups. However, at the 
baseline assessment, where the groups are equal on cognitive measures, the difference 
between groups, if present, are likely to be subtle enough that the greater variance 
associated with FS, as reported in previous studies (e.g. Morey et al., 2009), was expected 
to impact the ability of FS to detect group differences, whereas the MT was expected to 
be refined enough to do so. 
Objectives Summary. Evaluating measurement of hippocampal atrophy over time 
is important because greater atrophy has been linked to poorer clinical outcomes. 
Therefore, it is important to compare manually traced hippocampal volumes to the 
automated FreeSurfer volumes since they are two of the most commonly used techniques 
in these volumetric studies. If manually traced volumes were to generate a statistically 
significant distinction in asymptomatic individuals over time relative to the FreeSurfer 
volumes, then that could be evidence for the importance of using manual tracings over 
FreeSurfer in a clinical setting. Alternatively, if the two methods are not shown produce 
significant volume differences between groups, then that could be evidence for using the 
automated FreeSurfer technique over manual tracings. 
Method 
 
 
Participants 
 
 
This study made use of archival data. Participants were a subset of 60 healthy 
older adults. The participants were included from a larger sample of 459 adults from the 
community who were recruited via newspaper advertisement and met inclusion/exclusion 
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criteria (see below). Following a telephone screen, 81 individuals agreed to undergo a 
neuropsychological evaluation, APOE genotyping from blood samples, and a MRI scan. 
FreeSurfer volumes were not available for five participants and of the remaining 
participants, 60 received both neuropsychological testing and a MRI scan at the third 
follow-up assessment. At study entry, of the 60 participants 75% were female, the mean 
age was about 72 years (Mage = 71.6 years, SD = 4.5 years), and the mean education was 
about 15 years (Meducation = 14.9 years, SD = 2.6 years). The interval time from the first 
scan to the second scan was about 554 days (M = 553.9 days, SD = 33.9 days) and from 
the second scan to the third scan was about 1191 days (M = 1191.4 days, SD = 105.0 
days).  
For APOE genotyping, DNA was isolated with Gentra Systems Autopure 1.5 for 
Large Sample Nucleic Acid Purification and was amplified using a PCR method 
(Saunders et al., 1996). Family history was defined as a report of a clear clinical 
diagnosis of AD or a reported history of gradual decline in memory and other cognitive 
functions, confusion, or judgment problems without a formal diagnosis of AD prior to 
death, in a first-degree relative. Of the total 60 participants, 24 (40%) had at least one 
copy of the ε4 allele. Thirty-two participants (53.3%) had a positive family history, while 
28 (46.7%) did not have a family history.  
Inclusion into the study required a negative history of cognitive impairment 
and/or dementia, neurological disease or medical illnesses, major psychiatric disturbance 
(e.g. Geriatric Depression Scale score greater than 15), or substance use meeting DSM-
IV Axis I criteria.  In addition, all participants were right-handed, based on the Edinburgh 
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Handedness Inventory (Oldfield, 1971). Informed consent was obtained consistent with 
the Declaration of Helsinki and institutional guidelines established by the Medical 
College of Wisconsin Human Subjects Review Committee; all participants received 
financial compensation for their participation.  
Neuropsychological Assessment 
 
 
All participants underwent baseline and follow-up neuropsychological testing and 
were determined to be cognitively intact, based on local norms determined at study entry. 
To generate the normative data, 91 local individuals with similar age, education, and 
ethnicity were tested. Participants were considered ‘cognitively intact’ if they fell within 
at least one standard deviation of the population mean. Separate means were created for 
males and females. The neuropsychological battery included the Mini-Mental State 
Examination (MMSE) (Folstein, Folstein, & McHugh, 1975), Mattis Dementia Rating 
Scale-2 (DRS-2) (Jurica, Leitten, & Mattis, 2001; Mattis, 1988), Rey Auditory Verbal 
Learning Test (RAVLT) (Rey, 1958), Geriatric Depression Scale (Yesavage et al., 1983), 
and Lawton Instrumental Activities of Daily Living Scale (ADL) (Lawton & Brody, 
1969). The RAVLT and the DRS-2 was used to define decline. As such, these two tests 
are described in more detail below. All participants underwent a follow-up 
neuropsychological assessment approximately 18-months and 4.5 years after study entry. 
Alternate forms of the DRS-2 and the RAVLT were used during the initial follow-up 
examination for the majority of participants (see below). Because there is only one 
alternate form of the DRS-2, the DRS-2 Original version was used at study entry and at 
the 4.5-year follow-up.  
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The Dementia Rating Scale-2 (DRS-2) is intended for individuals over the age of 
55-years-old (Strauss, 2006). This cognitive screening measure incorporates five 
subscales, including Attention, Initiation/Perseveration, Construction, Conceptualization, 
and Memory (Strauss, 2006).  The individual subscale scores are then added together to 
create a Total score.  Individual subscale alpha coefficients range from .75 to .95 
(Vitaliano et al., 1984). Internal consistency of the Total score has been shown to be 
greater than .70 (Smith et al., 1994). Alternate form reliability for the Total score has 
been shown to be .82 (Schmidt, Mattis, Adams, & Nestor, 2005). Overall, the DRS-2 has 
been shown to have adequate reliability and vailidity coefficients.  Good construct 
validity, with strong correlations (r = .78) with the Mini-Mental State Exam, and as such 
has often been used to determine cognitive decline (Bobholz & Brandt, 1993).  
The RAVLT is a verbally mediated list learning test that includes 15 items (Rey, 
1958). The individual is asked to listen carefully as the list of 15 words is read aloud, and 
is then asked to recall as many words from that list as possible in any order. There are 
five total learning trials in which the participant listens to the list and recalls as many 
words as possible. Following the fifth trial, a second list of 15 novel words (i.e., a 
distractor list) is read and the individual is asked to recall this new list of words in any 
order. Immediately after this distracter list, the individual is asked to again recall as many 
words from the original list as possible. Following a 20-minute delay, the individual is 
again asked to recall the original list. Finally, the individual is asked to correctly identify 
words from the original list during a verbal discrimination task. Thus, this measure 
evaluates an individual’s ability to learn new information, retain this new information in 
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the presence of interference, and recognize this information among distracters (Knight, 
McMahon, Skeaff, & Green, 2007). The RAVLT has shown good reliability, particularly 
for the total score (Trials 1-5), delay recall score and Trial 5 (Strauss, 2006), with the 
internal reliability of the total score demonstrating a coefficient alpha of .90 (van den 
Burg & Kingma, 1999). Strong convergent validity (r > .75) has also been demonstrated, 
particularly between the delay recall and total score (van den Burg & Kingma, 1999), as 
well as other verbal memory measures, including verbal memory tests in the Wechsler 
Memory Scales (e.g., see Salthouse, Hancock, Meinz, & Hambrick, 1996). The stability 
of the test has been established in populations over 65-years-old (Estevez-Gonzalez, 
Kulisevsky, Boltes, Otermin, & Garcia-Sanchez, 2003; Knight et al., 2007) and it has 
been used frequently in the literature to assess cognitive decline over time (Estevez-
Gonzalez et al., 2003; Woodard et al., 2010). As many as six alternate versions have been 
created with similar difficulty (Hawkins, Dean, & Pearlson, 2004), with alternate form 
reliability typically greater than .60 (Strauss, 2006). In the present study, three different 
forms were used for the majority of participants.  
During the data collection process, test administration errors were made in which 
10 participants were given the same version of the RAVLT at the 18-month and 4.5-year 
follow-up. Data from these 10 participants were reviewed and two of the 10 participants 
met criteria for Decline, whereas the remaining eight participants met criteria for Stable. 
All 10 participants were retained in analyses to maintain sufficient power. See limitations 
section for further discussion. 
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Image Acquisition 
 
 
Anatomical images were acquired as part of a larger MRI protocol conducted on a 
General Electric (Waukesha, WI) Signa Excite 3.0 Tesla short bore scanner. High 
resolution, three-dimensional spoiled gradient recalled at steady-state (SPGR) anatomic 
images were acquired (TE = 3.9 ms; TR = 9.5 ms; inversion recovery (IR) preparation 
time = 450 ms; flip angle = 12 degrees; number of excitations (NEX) = 2; slice thickness 
= 1.0 mm; FOV = 24 cm; resolution = 256 x 224). Foam padding was used to reduce 
head movement within the coil. 
Measurement of Hippocampal Volumes 
 
 
FreeSurfer Hippocampal Volumes. FreeSurfer is a free software application for 
neuroimaging analyses and is available by download (http://surfer.nmr.mgh.harvard.edu). 
In the present study, FreeSurfer version 5.1.0 was used. Among other available tools, 
FreeSurfer can be used to label subcortical structures, such as the hippocampus. The 
details of FreeSurfer procedures can be found in previous publications (e.g., see Fischl & 
Dale, 2000). Briefly, brain matter is isolated by removing any non-brain matter after 
correcting for motion effects and applying the average of the volumetric T1 images 
(Segonne et al., 2004). A Talairach transformation, to adequately orient the brain into a 
standard reference space, is applied to the remaining images before deep gray and white 
matter is segmented (Fischl et al., 2002). An automatic deformation of the surface 
identifies the greatest shift in signal intensity from the cerebrospinal fluid (CSF) to the 
gray matter (Segonne, Pacheco, & Fischl, 2007), which is then used to create a boundary 
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between structures, such as the hippocampus, that are adjacent to CSF filled ventricles by 
applying an intensity normalization (Sled, Zijdenbos, & Evans, 1998) and tessellation of 
the boundary (Fischl, Liu, & Dale, 2001). Finally, Freesurfer performs a topology 
correction of the identified brain matter (Fischl et al., 2001). The standard protocol for 
longitudinal processing with FS Version 5.1.0 was used for the present study (Reuter, 
Rosas, & Fischl, 2010).  Briefly, the longitudinal data are first segmented cross-
sectionally. Next, a template, or a base, is created from the cross-sectional segmentations 
to create an unbiased comparison point. Then, the cross-sectional scans are re-sampled to 
this template to allow for the detection of change over time. The creation and use of an 
unbiased template within this longitudinal processing stream works to reduce random 
variation inherent across multiple scans (Reuter et al., 2010).  
Manually Traced Hippocampal Volumes. Hippocampal volumes from all three 
time points were manually traced in AFNI (Cox, 1996) on a T1-weighted SPGR image by 
three raters (one primary rater and two reliability raters) blinded to participant group 
membership, time point and genetic risk status. The segmented hippocampal mask 
generated from FreeSurfer was overlaid on the individual’s anatomical image. Left and 
right hippocampal volumes were traced independently. In the sagittal plane, raters edited 
the overlaid FreeSurfer mask to exclude any non-hippocampal voxels included by 
FreeSurfer and to add any hippocampal voxels excluded by FreeSurfer. In the coronal 
plane, the mask was further refined to exclude the fimbria while retaining hippocampal 
structures (alveus, uncal apex, cornu ammonis, subiculum, gyrus of retzius and fasciola 
cineria) as outlined in (Duvernoy, 2005).  
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Using the atlas, the primary rater (AMB) met with the two alternate raters to 
discuss the goal and method of manual tracing. Included, was training the alternate raters 
on the proper use of Linux and AFNI as they function as a platform for completing 
manual tracings. The primary rater demonstrated a manual tracing step-by-step, and then 
assigned practice tracings for the alternate raters. Once the practice tracings were 
complete, the primary rater reviewed the overlaps and met again with the alternate raters 
to discuss areas of agreement and disagreement, as they relate to the training atlas. This 
process began with face-to-face meetings, then continued with internet mediated 
meetings as needed until all raters achieved sufficient reliability (ICC > .80). 
The primary rater completed all manual tracings, and the two additional raters 
traced a total of 10% of different randomly selected scans (5% each).  A script was 
created to compare the alternate tracing to the primary tracing, by generating a quantity 
of voxles uniquely identified by the alternate rater and primary rater, respectively, as well 
as the overall agreement between the two tracings. The unique voxels were then summed 
to the overlap voxels for each tracer, and that total value was then entered into the 
intraclass correlation (ICC) statistic. Within SPSS, the ICC Statistic was chosen, with the 
Two-way Mixed Model and Absolute options selected. The resulting ICC values for the 
two raters with the primary tracer were 0.93 and 0.94, respectively, see Figure 1. 
Additionally, intra-rater drift (i.e., test-retest reliability) was also assessed on the primary 
rater. A total of 5% of tracings were retraced blind to participant group or characteristics 
and blind to the original tracing. The intraclass correlation was 0.95 (see Figure 1). 
Although the ICC values for the alternate raters and the primary rater were high, there 
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was a notable absolute volume difference. The average volume for the first alternate rater 
was 2997 mm3, and was 2528 mm3 for the respective tracings for the primary rater. The 
average volume for the second alternate rater was 2038 mm3, and was 2446 mm3 for the 
respective tracings for the primary rater. This discrepancy suggests that the primary tracer 
was slightly more conservative compared to the first alternate rater, yet slightly more 
liberal compared to the second alternate rater. Together, this may suggest that had either 
one of the alternate rater been the primary rater, the overall set of manual tracings my 
have been systematically more conservative or liberal than the tracings in the present data 
set. Despite these mean volume differences, the ICC values were sufficient and strongly 
correlated with one another. Additionally, this method of manual hippocampal 
measurement has been used and accepted in previous publications (Hantke et al., 2013; 
Woodard et al., 2009; Woodard et al., 2010). 
Hippocampal volumes were normalized by using a covariance approach (Buckner 
et al., 2004; Raz et al., 2005) to account for individual variation in brain size using the 
following formula: 
Adjusted volume = raw volume – b * (ICV – mean ICV) 
Where the adjusted volume is the intracranial volume (ICV) corrected volume that was 
entered into analyses. Raw volume is the volume of the target region of interest (ROI) 
(i.e. hippocampus). The ‘b’ is the slope of a regression of a region of interest volume on 
the ICV, such that one slope value was generated per ROI to represent the slope for the 
sample. Finally, mean ICV is the average ICV, which is generated by FreeSurfer, for the 
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whole sample. This approach to normalization accounts not just for ICV, but also the 
relative effects of ICV. 
Definition of Cognitive Decline. Cognitive decline was defined as a reduction 
from baseline performance to 4.5-year follow-up performance of at least one standard 
deviation (SD) on at least one of the three principal outcome indices (DRS-2 total score, 
RAVLT Sum of Trials 1-5 [T1-5], RAVLT Delayed Recall [DR]). A residualized change 
score was generated for each individual and each cognitive measure by predicting follow-
up scores using baseline scores; this procedure adjusts for baseline performance, practice 
effects, and regression to the mean (McSweeny, 1993; Temkin, Heaton, Grant, & 
Dikmen, 1999). Participants with standardized residuals of -1.0 or lower were assigned to 
the cognitively declining group. The remaining participants were classified as cognitively 
stable.  
Power Analysis. A power analysis for each hypothesis was conducted using 
GPower. In previously discussed studies with similar methodology, medium effect sizes 
have been found when comparing hippocampal generating methods between clinical 
groups (e.g. Morey et al., 2009). Therefore, the medium effect sizes that were anticipated, 
along with repeated measures of Method (FS and MT) and Time (Baseline, 18-month 
follow-up, 4.5-year follow-up) for the second hypothesis were entered into a power 
analysis for the first and second hypothesis separately. Additionally, a high correlation 
among repeated measures was expected because the scanner was consistent throughout 
data acquisition of this longitudinal study, and FreeSurfer is an automated method that 
demonstrates high reproducibility (R = .82) of hippocampal volumes across multiple 
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scans (Morey et al., 2009). Furthermore, the manually tracings, which may be more 
susceptible to variation over time, were mixed across sessions and the raters completing 
the manual edits were blinded to session. Thus, the risk of poor correlation over time was 
reduced.  
Therefore, the power analysis for the first hypothesis indicated that for a mixed 
ANOVA, with partial eta square set at .06 for a medium effect, alpha at 0.05, power set at 
0.8, two groups (Declining and Stable), four measurements (MT, FS, Left, Right), 0.8 
correlation among repeated measures, 22 participants would be required. Given that there 
are 60 participants in the present study, the proposed design should have sufficient power 
to test the first hypothesis. The power analysis for the second hypothesis indicated that 
for a mixed ANOVA, with partial eta square set at .06 for a medium effect, as discussed 
above, alpha at 0.05, power set at 0.8, two groups (Declining and Stable), six 
measurements (MT and FS volumes measured at three time points), 0.8 correlation 
among repeated measures, 24 participants would be required. These power analyses 
suggest that the present study should have sufficient power. 
Statistical Analyses 
 
 
Hypothesis 1 aimed at assessing for group differences at baseline, while 
Hypothesis 2 assessed group differences over time in a longitudinal study. A 2 Method 
(FS, MT) x 2 Side (Left, Right) x 2 Group (Declining, Stable) mixed ANOVA was 
conducted to test Hypothesis 1. A 3 Time (baseline, 18 months, 4.5 years) x 2 Method 
(FS, MT) x 2 Group (Declining, Stable) mixed ANOVA was conducted to test 
42 
 
Hypothesis 2. Statistics were analyzed using SPSS version 18.0 for Windows. The level 
of significance was set at alpha = .05 for initial analyses. 
Results 
 
 
Identification of Cognitive Decline 
 
Out of the 60 total participants, 15 (25%) declined by at least one standard 
deviation on at least one of the principal neuropsychological outcomes measures (DRS-2, 
RAVLT Trials 1-5, RAVLT Delay). These 15 participants comprised the “Declining” 
group, whereas the remaining 45 participants comprised the “Stable” group.  
Ten of the 15 Declining participants (68%) compared with only 14/45 of the 
Stable participants (31%) carried an ε4 allele (Fisher’s Exact Test p = .031) (see Table 1).  
The groups did not differ on other demographic variables, including age, education, 
family history or sex (see Table 1). Baseline performance on the DRS-Total, RAVLT 
Trials 1-5 and RAVLT Delay also did not differ between groups (see Table 1). Yet, as 
expected, Declining participants had poorer scores than Stable participants on all three 
neuropsychological measures at the 4.5 year follow up [DRS-2 Total, F (1,14.99) = 6.9, p 
= .019, η2 = .06; RAVLT Trials 1-5, F (1,18.27) = 10.41, p = .005, η2 = .01; RAVLT 
Delay, F (1,17.00) = 15.82, p = .001, η2 = .02. Values are adjusted for significant tests of 
homogeneity of variances, see Table 2]. 
Hypothesis 1 
 
 
The ability of FreeSurfer and manual tracings to distinguish baseline hippocampal 
volumes in future Declining participants from Stable participants was assessed using a 2 
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Method (FS, MT) x 2 Side (Left, Right) x 2 Group (Declining, Stable) mixed ANOVA. 
There were significant main effects for Method (FS volumes > MT volumes), F (1, 57) = 
625.87, p < .001, η2 = .915, see Figure 2), and Side (right > left; F (1, 57) = 23.64, p < 
.001, η2 = .290, see Figure 3). There was no main effect of Group, F (1, 57) = .514 p < 
.476, η2 < .009, see Figure 2. 
Further clarifying the main effects of Method and Side, there was a significant 
interaction between Method and Side, F (1, 57) = 12.326 p = .001, η2 = .175. Post hoc 
analyses revealed that within each method, right hippocampal volumes were larger than 
left, and that FS volumes were greater than MT volumes for both the left and right 
hippocampus (left hippocampus: p < .001, η2 = .897; right hippocampus: p < .001, η2 = 
.910; see Figure 4). The 2- and 3-way interactions involving Group were not significant: 
a) Method x Group, F (1, 57) = .131, p = .718, η2 = .002, see Figure 5; b) Side by Group, 
F (1, 57) = 1.344, p = .251, η2 = .023, see Figure 6; c) Method by Side by Group, F (1, 
57) = 1.713, p = .196, η2 = .029, see Figure 7. 
Additional comparison between the hippocampal measurements was conducted 
with Bland-Altman plots (Bland & Altman, 1999). This approach, also used in similar 
studies (Sanchez-Benavides et al., 2010), depicts the consistency between FS and MT by 
plotting the mean difference between the two measures against the mean for each 
participant. As can be seen in Figures 8, 9 and 10 the vast majority of hippocampal 
volumes fell within the expected range and neither methodology exhibited evidence of 
systematic error. Thus, other than overall volume differences between methods, FS and 
MT appear to measure hippocampal volume in consistent and comparable ways. 
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One possibility for not finding significant baseline group effects in the mixed 
ANOVA may be the occurrence of low power to detect such differences. Although the 
power analysis and previously discussed literature indicated that this sample size would 
be sufficient power to test for differences, it is possible that there is a degree of variability 
in the present data that is leading to insufficient power. It may also be the case that no 
group differences were detected because there were no group differences to detect in 
these data, or the effect is very small. As originally proposed, to further assess these two 
contrasting possibilities, the results were reconsidered adjusting the alpha level from .05 
to .10 to better protect against possible Type II error. Still, this adjustment made no 
difference with respect to significance of effects. Another possibility for not finding 
group differences may be that the data are influenced by another variable. 
Because APOE ε4 status has been shown to be a meaningful factor in cognitive 
decline, a follow-up mixed ANOVA including APOE status was conducted to determine 
if APOE inheritance was greatly influencing the ability to detect differences between 
Stable and Declining participants. Supporting the value of APOE, a Method x Side x 
APOE mixed ANOVA revealed a significant interaction F (1, 58) = 7.732, p = .007, η2 = 
.118, see Figure 11. Post hoc analyses reveal that within each method, APOE status did 
not differ within left and right volumes.  Additionally, ε4-negative participants showed a 
pattern of right greater than left hippocampal volumes as measured by both FS and MT. 
Notably, ε4-positive participants showed the pattern of right greater than left 
hippocampal volumes as measured by FS, but not MT, see Figure 11. Therefore, it may 
be that APOE status is also an important variable in distinguishing between groups, and 
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that using a combination of variables, such as hippocampal volume and APOE status may 
be useful.  
To further assess the clinical meaningfulness of the interaction, Decline status was 
added to the mixed Method x Side x APOE ANOVA. This 4-way mixed ANOVA 
revealed an interaction trend, F (1, 56) = 3.315, p = .074, η2 = .056, see Figure 12. The 
same FS >MT effects remained, (p’s < .001), but post hoc analyses revealed specific 
differences between groups. In particular, ε4-negative Stable participants had greater 
right than left hippocampal volumes, as measured by both FS (p < .001) and MT (p = 
.004), but ε4-negative Declining participants (n = 5) had larger right than left volumes, as 
measured by FS (p =.003), but not MT (p = .639). Furthermore, ε4-positive Stable 
participants had larger right than left volumes as measured by FS (p =.021), but not by 
MT (p = .298), whereas ε4-positive Declining participants did not differ, see Figure 12.  
It may be that with additional subjects to improve power, this interaction may become 
statistically significant.  
Further clarifying this marginally significant 4-way interaction, a Method x 
Decline x APOE mixed ANOVA was separately conducted for left and right hippocampi. 
The results of these analyses yielded a significant main effect of Method for both left (p < 
.001, η2 = .888) and right hippocampi (p < .001, η2 = .899), see Figure 13, with FS 
producing larger volumes than MT. Left, but not right, hippocampal volumes showed a 
trend for a Method by APOE interaction F (1, 56) = 3.936, p = .052, η2 = .066. Post hocs 
show right volumes were greater than left in both ε4-negative and ε4-positive participants 
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(p’s < .001), but that within method, ε4-positive participants did not differ from ε4-
negative participants (FS: p =.405; MT: p = .341), see Figure 13. 
The relationship between hippocampal volume measurement, APOE, and 
cognition was further assessed in a way that may be less limited by low power and 
possibly suboptimal groups distinction. To assess these relationships, hierarchical 
multiple regression analyses were conducted to predict the change in cognitive 
performance from baseline to the 4.5 year assessment. The residualized change scores for 
RAVLT Trials 1-5, RAVLT Delay, and DRS-2 Total were used as the predicted variables 
for each regression because this technique adjusts for baseline performance, practice 
effects, and regression to the mean.  Initial regressions with age, sex, and education 
entered in at Step 1, and with APOE and hippocampal volume entered in at Step 2, 
showed that demographic factors did not significantly contribute to the models predicting 
cognitive change, but APOE and hippocampal volume provided some predictive utility. 
Therefore, because the residualized change score inherently adjusts for some variance 
that may be associated with demographic factors, follow-up regressions were conducted 
replacing the demographics for hippocampal volume in Step 1 and APOE in Step 2. 
Given the relatively small sample size and the high inter-correlations of MT and FS, no 
more than three predictor variables were included and each method was entered into 
separate regressions.  
Models 1-4 attempted to predict RAVLT 1-5 with hippocampal volume entered at 
Step 1 and APOE entered at Step 2, see Table 3. Model 1, which included total FS 
volume, and Model 2, which included left and right FS volumes, were not significant (p = 
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.302 and p =.425, respectively). Similarly, Models 3 and 4, which included total MT 
volume and left and right MT volumes, respectively, were not significant (p’s < .280). 
Next, Models 1-4 were used to predict RAVLT Delay score, see Table 4. Model 1 
showed that FS total volume alone was not significant (p = .087), but the model became 
significant after adding APOE (p = .002). Left and right FS volumes alone were 
marginally significant (p = .053), but again adding APOE significantly improved the 
overall predictive ability of Model 2 (p =. 004). In Model 3, total MT volume marginally 
predicted RAVLT Delay alone (p = .062), but the overall model improved when adding 
APOE (p .002). Separate left and right MT alone were not predictive (p = .151), but 
together with APOE, Model 4 was significant (p =.007). Finally, Models 1-4 were used 
to predict DRS-2 Total scores, see Table 5. As with RAVLT 1-5, Model 1 with FS total 
volume and Model 2 with left and right FS volumes were not significant (p = .093 and p 
= .108, respectively). A similar pattern of not significantly predicting DRS-2 Total score 
was found for Model 3, using MT total volume, and Model 4, using left and right MT 
volumes (p = .311 and p = .509, respectively). These regressions may suggest that 
baseline hippocampal volume may provide limited contribution in predicting change in 
cognitive performance, but is not necessarily sufficient without the inclusion of APOE. 
Another useful method less restricted by small cell sizes and power is the receiver 
operating characteristic (ROC) curve, which has been used in similar studies (Cherbuin et 
al., 2009; Lehmann et al., 2010; Tae et al., 2008). This approach provides an indication of 
sensitivity and specificity of a measure, in this case the ability of FS and MT to correctly 
classify decline.  The results of the ROC curve with baseline volumes suggest that neither 
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baseline MT nor FS volumes correctly classified decline above chance levels, (all area 
under the curve (AUC) < .505, p’s > .08) see Table 6, Figure 14.  
Finally, sagittal and coronal overlap images of FS and MT baseline volumes for 
one Declining and one Stable participant were created, see Figures 15 and 16.  A 
qualitative review reveals a degree of tissue included by FS, but not MT around the 
boarder of the hippocampus. There were indications of possible over-inclusion anteriorly 
adjacent to the amygdala by FS. This single participant depiction supports the 
quantitative finding of FS generating overall larger volumes than MT. 
Hypothesis 2 
 
 
To test the hypothesis that FreeSurfer and manually traced hippocampal volumes 
would vary by group at different time points was assessed by conducting a 3 Time 
(baseline, 18 months, 4.5 years) x 2 Method (FS, MT) x 2 Group (Declining, Stable) 
mixed ANOVA, with alpha = .05. There were significant main effects for both Time, F 
(2, 57) = 27.85, p < .001, η2 = .324, see Figure 17, and Method, F (1, 57) = 635.57 p < 
.001, η2 = .916, see Figure 18.  Specifically, FS volumes were larger than MT volumes.  
Post hoc comparisons showed that the Time main effect reflected smaller volumes at 
each successive time point.  There was no significant main effect for Group, F (1, 57) = 
1.535, p = .220, η2 = .026, see Figure 19. 
Importantly, there was a significant interaction of Group by Time, F (1, 57) = 
3.966, p = .022, η2 = .064, see Figure 20. Post hoc analyses revealed that in Stable 
participants, 18-month volume did not differ significantly from baseline (p = .168), but 
volume at 4.5 years was significantly smaller than at baseline (p < .001) and at 18 months 
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(p = .001) compared to baseline. However, the Declining participants had a more 
progressive pattern of atrophy, where hippocampal volume was smaller each time 
successive time point (p’s < .012). Yet, no contrasts differed significantly between groups 
at any time point, see Figure 20. None of the other interactions reached significance: a) 
Group by Method, F (1, 57) < .001, p = .996, η2 < .001, see Figure 21; b) Method by 
Time, F (1, 57) = 2.387, p = .096, η2 = .040, see Figure 22; c) Group by Method by Time, 
F (1, 57) = .552, p = .577, η2 = .009, see Figure 23. Based on the same potential issues 
with power as were discussed for Hypothesis 1, the analysis was reconsidered using an 
adjusted alpha = .10, but no additional effects reached significance using this cutoff. 
Again, this may suggest that the absence of group differences may not be due to low 
power, or it may suggest that if group differences are present, the effects are very small. 
To further explore longitudinal changes in hippocampal volume, APOE 
inheritance was included in the analysis. A separate mixed Time x APOE ANOVA for 
MT and FS was conducted. These analyses revealed a significant Time x APOE 
interaction as measured by FS [F (2, 57) = 4.192, p = .017, η2 = .067], but not MT [F (2, 
57) = .389, p = .678, η2 = .007], see Figure 24. Post hoc analyses revealed that when 
measured by FS, the volumes of ε4-negative participants changed little from baseline to 
the 18-month follow-up (p =.164). Yet significant reduction was apparent at the 4.5-year 
follow-up, compared to the 18-month follow-up and baseline (p = .019, p =.006, 
respectively). In contrast, ε4-positive participants had somewhat smaller hippocampal 
volumes at the 18-month follow-up compared to baseline (p = .063), and significantly 
smaller 4.5-year volumes than baseline and the 18-month follow-up (p’s < .001). At each 
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time point, hippocampal volumes did not differ between ε4-positive and ε4-negative 
participants. Yet, there was no time by APOE interaction as measured by MT, such that 
ε4-positive and ε4-negative participants did not differ at each time point or over each 
time point, see Figure 24.  
As with the first hypothesis, additional analyses were done to assess the 
relationship between hippocampal volume, APOE, and cognitive performance, see Table 
7. Hippocampal volume at the 4.5-year follow-up appears to be more strongly related to 
cognitive outcome than APOE inheritance. In particular, a Pearson correlation 
demonstrated many strong correlations between cognitive performance and MT and FS 
volumes at the 4.5-year follow-up.  Notably, although APOE is significantly correlated 
with decline status, t-test comparisons between APOE and hippocampal volumes at the 
4.5-year follow-up were not significant.  Similarly, a t-test comparing cognitive measures 
to APOE status revealed a significant association with RAVLT Delay score at the 4.5-
year follow-up, wherein ε4-negative participants had higher scores than ε4-positive 
participants (p = .003), yet all other comparisons were not significant, see Table 7.  
To determine if cognitive performance could be predicted by hippocampal 
volume and APOE at the 4.5-year follow-up, hierarchical multiple regressions were 
conducted. The Step and Model structures for this regression analysis on 4.5-year 
volumes were identical to those used for the first hypothesis on baseline volumes. 
Residualized change scores were used as the predicted outcomes, with 4.5-year 
hippocampal volumes and APOE as the predictive variables, because demographics were 
not significantly contributing. Models 1-4 attempted to predict RAVLT 1-5 performance, 
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see Table 8. Model 1, using FS total volume alone was significant (p = .039), but adding 
APOE reduced the overall significance of the model (p = .091). In Model 2, using left 
and right FS volumes alone or with APOE was not significant (p =.142). In Model 3, MT 
total volume alone predicted RAVLT 1-5 (p =.014), and remained significant after adding 
APOE (p = .042). Left and right MT volumes alone were significant (p = .037), but 
adding APOE to Model 4 marginalized the significance of the overall model (p = .068). 
Models 1-4 were then used to predict RAVLT Delay score, see Table 9. In Model 1, FS 
total volumes alone (p =.027) and with APOE (p = .001) significantly predicted cognitive 
performance. Left and right FS volumes alone were marginally significant (p =.058), but 
the overall model became significant when adding APOE (p = .004), Model 2. A similar 
pattern was found with MT, such that total volumes (p =.052), as well as left and right 
volumes (p =.083) alone were marginally significant, whereas adding APOE significantly 
enhanced the overall models (Model 3: p = .003; Model 4: p = .007). Finally, Models 1-4 
were used to predict DRS-2 Total score, see Table 10. Model 1, with FS total volume 
alone was significant (p =.008), and remained significant after adding APOE (p = .019). 
This same pattern was found for Model 2, using left and right FS volumes (p = .031). 
With MT, total volume alone was significant (p = .044), but adding APOE reduced the 
overall significance of the model (p = .089), Model 3. Left and right MT volume alone 
was significant (p =.026), and the overall model remained significant when adding APOE 
(p =.030), Model 4. 
To supplement the previous comparison of hippocampal volumes at each time 
point across groups, a separate analysis was conducted to assess the degree of atrophy 
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from one time point to another. This evaluation allowed for another observation of rate of 
atrophy over a period of time between groups across methods. Therefore, three change 
scores were computed for each method: 1) change from baseline to 18-month follow-up; 
2) change from 18-month follow-up to 4.5-year follow-up; and 3) change from baseline 
to 4.5-year follow-up. These change scores were entered into three separate 2 Method 
(FS, MT) x 2 Group (Declining, Stable) ANOVA tests, with alpha = .05. The results 
revealed no significant differences between Declining and Stable participants in the 
amount of change between interval assessments: a) change from baseline to 18-month 
follow-up, FS: p =.110; MT: p =.500; b) change from 18-months to 4.5 years: FS: p 
=.094; MT: p =.489; c) change from baseline to 4.5 years FS: p = .067 (after accounting 
for violation of homogeneity of variance); MT: p = .163, see Figure 25. 
Although there were no significant interactions when comparing the degree of 
change from one time point to another between Group and Method, there was a notable 
finding when assessing the degree of change between time points with hippocampal 
volume and APOE. A one-way ANOVA revealed the change in FS volume to the 4.5-
year follow-up from baseline and the 18-month assessment differed by APOE (p = .023 
and .029, respectively).  For both change intervals, ε4-positive participants demonstrated 
greater change than ε4-negative participants. These were the only two significant findings 
with the ANOVA comparing hippocampal volumes and APOE, see Table 7. 
Discussion 
 
 
Recently revised diagnostic criteria for Alzheimer’s disease (AD) (McKhann et 
al., 2011) urge for further research of biological factors associated with AD, such as 
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hippocampal volume, in an effort to identify presymptomatic individuals who will 
eventually convert to AD (Sperling et al., 2011). To date, studies have been inconsistent 
as to whether individuals at risk for AD and those who eventually experience cognitive 
decline have smaller baseline hippocampal volumes than those who remain healthy 
(Burggren et al., 2008; Cohen et al., 2001; Jak et al., 2007; Kaye et al., 1997; Woodard et 
al., 2010). Furthermore, the rate of atrophy in presymptomatic individuals has as of yet 
seen only very limited exploration, and has produced somewhat inconsistent results. The 
disparate findings may be in part related to methodological differences in hippocampal 
volume measurement (i.e. FreeSurfer versus manual tracings). Therefore, the current 
study aimed to investigate the utility of hippocampal volume in a sample of cognitively 
intact elders at risk for AD measured over three time points.  At the 4.5-year follow-up, a 
subsample of individuals demonstrated cognitive decline. Hippocampal volumes as 
measured by FreeSurfer (FS) Version 5.1.0 were directly compared to manually traced 
(MT) hippocampal volumes at all three time points to determine if one method was 
superior to another at detecting meaningful group differences. More specifically, the first 
hypothesis was that MT, but not FS, would detect group differences at baseline between 
eventual Declining and Stable participants. The second hypothesis was that the rate of 
hippocampal atrophy from the baseline to the 4.5-year follow-up assessment would differ 
between FS and MT, such that MT were expected to show a greater amount of atrophy 
between groups compared to FS. 
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Aim 1: Baseline Hippocampal Comparisons Between Method, Side and Group 
  
 
General baseline hippocampal volume differences.  
 
 
The first aim of the study was to compare baseline hippocampal volumes, as 
measured by FS to those measured by MT, and to assess for possible group differences in 
the hippocampal volume of cognitively healthy elders who later declined compared to 
those who remained stable. As expected, FS yielded overall larger hippocampal volumes 
relative to MT.  This finding is very consistent with the literature demonstrating that FS 
produces larger hippocampal volumes than MT (Burggren, Small, Sabb, & Bookheimer, 
2002; Cherbuin et al., 2009; Jak et al., 2007; Lehmann et al., 2010; Morey et al., 2009; 
Sanchez-Benavides et al., 2010). FreeSurfer is a segmentation technique initially 
developed to delineate cortical structures (Fischl, 2012; Fischl & Dale, 2000). Although a 
relative strength of FS is its automated nature that allows for rapid segmentation of high 
quantities of data, the ability of FS to segment subcortical structures has been less 
precise, resulting in consistently larger reported hippocampal volumes (Burggren et al., 
2002; Cherbuin et al., 2009; Jak et al., 2007; Lehmann et al., 2010; Morey et al., 2009; 
Sanchez-Benavides et al., 2010).  While this version of FS, Version 5.1.0, was thought to 
have made improvements to subcortical segmentation (Van Leemput et al., 2009), the 
present data suggest that compared to the ‘gold standard’ manual tracings, it continues to 
yield larger overall hippocampal volumes. This discrepancy between the methods is 
notable because when the method chosen differs between research studies, it may bias the 
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generalized findings and comparison across studies, which may be in part related to the 
inconsistencies within the literature.   
In the present study, baseline hippocampal volumes as measured by FS, were 52% 
larger than MT. This percentage is larger than the 26% larger volumes that have 
previously been reported in healthy individuals (Cherbuin et al., 2009), and is larger even 
than the 35% that has been documented in clinical samples (Tae et al., 2008). By side, the 
present study found 50% larger left and 54% larger right hippocampal volumes as 
measured by FS compared to MT. Again, these values are larger than the 23% larger left 
and 29% larger right hippocampal volumes that have previously been reported (Cherbuin 
et al., 2009). Furthermore, in the present study, the standard error of baseline FS volumes 
was 35% greater than MT. This variance is greater than the comparable variance between 
the two methods found in the previous study with healthy individuals (Cherbuin et al., 
2009). Yet, a greater variance associated with FS has been documented in other studies 
with clinical populations (Morey et al., 2009). Therefore, the present study provides 
further demonstration that even this newer version of FreeSurfer produces overall larger 
hippocampal volumes with greater variance compared to MT.  
Hippocampal volumes were 3624.4 mm3 on average for Declining and 3715.3 
mm3 for Stable participants in the present study. When examined by method separately, 
the manually traced volumes were 2917 mm3 and FS volumes were 4422.6 mm3, on 
average. Earlier studies have examined the histological and MRI generated volume of the 
hippocampus post-mortem. In a study that compared the post-mortem volume of the 
hippocampus in young individuals and elders who died of non-neurological causes to 
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patients with AD, the average volume was shown to decrease with age, with a dramatic 
reduction in AD (Simic, Kostovic, Winblad, & Bogdanovic, 1997). Specifically, the 
authors showed the volume of the hippocampus in the younger sample, with a mean age 
of 30-years-old, was 3,731 mm3, hippocampal volume was 3,484 mm3 in the control 
group (mean age of 80 years), and was 2,409 mm3 in those with AD (mean age 84.4 
years) (Simic et al., 1997). Additionally, another study comparing post-mortem 
histological volumes to MRI volumes found very strong correlations between the MRI 
and histological measurements (Bobinski et al., 2000). The volumes for the MRI 
measurements were 3083 mm3 for the control and 2169 mm3 for the AD group, and the 
histology volumes were 3203 mm3 and 2257 mm3 for the two groups, respectively 
(Bobinski et al., 2000). Together, these studies suggest that the manually traced 
measurements obtained in the present study may be a slight under-quantification of 
expected volumes for healthy elders and those that might be on a mild disease trajectory, 
whereas the FS volumes may be producing greater over-estimation of true hippocampal 
volume.  
One explanation for the observed volume differences between methods in the 
present study is that FS is yielding larger volumes than expected. Yet, another possible 
explanation is that manual tracing is providing an underestimation of true hippocampal 
volume. This latter explanation may also provide rationale as to why the FS volumes 
were 52% larger in the present study, when earlier studies with healthy and clinical 
samples have found 26% and 10-35% greater FS volumes, respectively (Cherbuin et al., 
2009; Tae et al., 2008).  The histological studies on post-mortem hippocampi within this 
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population may suggests that slight biases in both methods may be contributing to the 
greater difference between FS and MT observed in the present study. That is, the 52% 
difference may be mediated by a slight under-estimation of manually traced volumes and 
an over-estimation by FS. Together, the contrasting biases between the two approaches 
may have led to the overall greater amount of difference between the two methods 
compared to previous studies. 
Laterality baseline hippocampal volume differences. 
 
 
In addition to FS yielding larger volumes than MT, there also was a laterality 
difference detected in the present study where baseline right hippocampal volumes were 
about 5% greater than left volumes. Although many similar studies collapse across 
hemisphere to explore a “total hippocampal” volume (Henneman et al., 2009) and many 
studies have not found laterality differences (Kaye et al., 1997; Raz et al., 2004; Sanchez-
Benavides et al., 2010), differences between left and right hippocampi in various samples 
have been well documented (Jack et al., 2003; Shi, Liu, Zhou, Yu, & Jiang, 2009; 
Woodard et al., 2009). Furthermore, the present study demonstrated a marginally 
significant interaction between side and APOE inheritance. Compared to the left, the 
right hippocampus was 3% larger in ε4-positive and 7% larger in ε4-negative 
participants. Additionally, compared to ε4-negative participants, the left hippocampus 
was 1% larger, but the right hippocampus was 4% smaller in ε4-positive participants. 
These marginally significant findings may build upon previous studies that have not 
found early APOE risk differences (Burggren et al., 2002; Jak et al., 2007), by suggesting 
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that APOE may influence the right greater than left pattern that has been documented, 
even in asymptomatic individuals.  
In addition to cognitively healthy samples, as was the case in the baseline 
comparison of the present study, the pattern of right greater than left hippocampal volume 
has been found in later stages of AD, with indications of smaller differences between the 
hemispheres as the disease progresses (Shi et al., 2009). We previously demonstrated that 
individuals with MCI showed smaller left, and trending right, hippocampal volumes 
compared to those at risk and healthy controls, supporting the finding that the right 
hippocampus was larger than the left hippocampus (Woodard et al., 2009). Also 
consistent with the present study, a large-scale clinical trial of individuals with probable 
AD demonstrated right hippocampal volumes were approximately 5% larger than left 
hippocampal volumes (Jack et al., 2003). Taken together, data from the present study 
lend further support to the right greater than left hippocampal volume pattern reported in 
the literature, and further extend the possibility of laterality differences according to 
APOE inheritance in cognitively intact individuals. This may have important implications 
for understanding the role of APOE and its potential impact on hippocampal volume and 
structure, which may be contributing to the imposed risk for AD development. 
Laterality by method with baseline hippocampal volumes. 
 
 
In addition to showing overall right greater than left baseline hippocampal volume 
differences, the present study demonstrated that this pattern is discernable with both FS 
and MT. This finding is consistent with a recent paper directly comparing MT and FS in 
a sample of individuals with AD, MCI, cognitive complaints with normal 
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neuropsychological data, and healthy controls. In this previous study, both MT and FS 
detected larger right hippocampal volumes relative to left hippocampal volumes across 
all groups (Shen et al., 2010). Collectively, these data may suggest that regardless of 
which method is used to segment the hippocampus, right hippocampal volumes will 
likely be larger than left hippocampal volumes. This may have research and clinical 
utility in that, if lateral volume differences are expected, FS may be just as reliable as MT 
in detecting the relative difference to the left hippocampus.  Additionally, the laterality 
differences that are detected by both FS and MT may also be important as disease 
progresses. That is, if the left hippocampus is smaller than the right, then it may have a 
focally reduced amount of cognitive reserve, or a reduced ability to withstand disease 
insults relative to the right hippocampus. Given that memory impairment is a hallmark 
feature of AD (APA, 2000), and verbal memory is strongly represented by the left 
hippocampus (Reminger et al., 2004), it lends further support to the theory that the left 
hippocampus may be more susceptible to the early effects of dementia pathology 
(Thompson et al., 2007).  
Notably, the way in which cognitive change was measured in the present study 
was dependent upon verbal memory performance, as well as a general cognitive screen 
that included verbal memory in addition to other cognitive domains. That the declining 
individuals did not show a relative laterality difference compared to stable individuals 
may suggest that the left hippocampus has not necessarily experienced atrophy, but rather 
the laterality differences that were detected reflect the general asymmetry observed in the 
hippocampus (Honeycutt & Smith, 1995). 
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Stable and Declining comparisons with baseline hippocampal volumes. 
 
 
The hypothesis that Declining participants would have smaller baseline 
hippocampi than Stable participants, as measured by MT but not FS, was not supported in 
the present study. That is, the interaction between method and side did not differ between 
Stable and Declining participants, as expected, and neither FS nor MT baseline 
measurements differentiated Stable and Declining participants. This null finding is in 
contrast to an earlier study where we showed that individuals with smaller baseline 
hippocampal volumes were more likely to experience cognitive decline than individuals 
with larger baseline hippocampal volumes (Woodard et al., 2010). The present data are 
also in contrast to what we found in a previous analysis of unpublished data that showed 
MT, but not FS Version 5.0.0, detected smaller volumes in Declining participants 
compared to Stable participants.  
There are a few key distinctions between the present study and our previous 
studies involving hippocampal volume differences in eventually Declining individuals. In 
both of these previous studies, cognitive decline was determined based on cognitive 
change from baseline to the 18-month follow-up compared to the 4.5-year follow-up in 
the present study. Furthermore, while some participants in the present analyses were in 
included in the previous studies, the overall sample in the present study was 33% smaller 
than the previous prediction study (Woodard et al., 2010) and 20% smaller than the 
previous study comparing MT and FS over the 18-month interval (unpublished data). 
Therefore, although the power analysis for the present study indicated sufficient power 
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with the 60 participants in the present study, it is possible that this study suffered from 
low power, and as such was not able to detect group differences at baseline.  
Additionally, the earlier studies used a different version of FS (V 5.0.0, released 
August 2010) and a different set of manual tracings. That is, because the present study is 
a separate experiment comparing a different version of FS to MT, all included tracings 
were unique to this study. As such, another explanation for the lack of reproducibility is a 
susceptibility of human variance associated with the manual tracings, which has been a 
critique of this segmentation method (Cherbuin et al., 2009). Although inter-rater 
reliabilities were strong with the primary tracer (ICC = 0.93 and 0.94), as was the intra-
rater reliability (ICC = 0.95) to assess rater drift in the present study, it is possible that 
this set of hippocampal tracings varied somewhat from the tracings in the earlier study. 
Given that the primary tracer in the present study was also involved in the tracing of 
hippocampal volumes for the earlier study, and that the tracing method was identical, it is 
also likely that the differing results are due to a combination of the newer version of FS 
and a differently defined Decline group, with low power. 
Yet another explanation is the potential for cognitive inconsistency across time 
points that may have resulted in different cognitive groupings. That is, there may be 
natural variability in cognitive assessments across individuals that may influence group 
distinction when adding in an additional follow-up assessment.  Natural inconsistency in 
addition to a relatively narrow cognitive assessment, which included an administration 
error in one measure for a subset of participants, may also influence cognitive 
consistency and introduce variance into the participant groupings.  Given that the sample 
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size was relatively small, even a small amount of cumulative variance may have 
undermined the ability to detect group differences. 
Although in the present study MT were not shown to identify presymptomatic 
individuals, this method has been shown to detect volume difference in predementia 
individuals (Kaye et al., 1997). That is, an earlier study found smaller baseline 
hippocampal volumes in individuals who later decline compared to those who remain 
stable (Kaye et al., 1997), which suggest that the present study should have detected 
group differences. Yet, there are several notable differences between the Kaye et al. study 
and the present one that may account for the inconsistencies. First, although the 
resolution between scans were similar, the original Kaye et al. study used a 1.5T with 4 
mm slices, while the present study used a 3T with 1 mm slices. It is possible that with 
4mm slices, Kaye et al. was more vulnerable to partial voluming effects, or the 
occurrence of including tissue belonging to adjacent structures that were partially, but not 
fully representative of hippocampal volume. Partial voluming may have been more likely 
to occur in the group with more poorly differentiated anatomy due to disease than the 
control group. Additionally, the predementia group differed in age and cognition at the 
baseline assessment in Kaye et al., whereas the Stable and Declining groups in the 
present study were not different across these variables at baseline. Furthermore, the 
participants in the Kaye et al. study were older at study entry (at least 84 years old, with a 
mean age of 92), whereas those in the present study were at least 65 years old at study 
entry (mean age of 72 years). This may suggest that the present study is asking a similar 
theoretical question about two decades prior to the sample in the Kaye et al. study.  
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While the present study did not find group differences in presymptomatic 
individuals, studies have shown that FS and MT are able to distinguish between 
symptomatic and asymptomatic individuals. The present study is consistent with 
Lehmann et al. (2010) who documented larger FS volumes relative to MT in AD, 
Semantic dementia, and controls, but Lehmann et al. also found both methods to correctly 
classify the different groups. Similarly, a study comparing FS and MT in MCI, AD, and 
controls found 10% larger FS than MT volumes, with acceptable interchangeability 
between the two methods as demonstrated by Bland-Altman plots (Sanchez-Benavides et 
al., 2010).  Further still, 35% larger FS volumes, with greater associated variance, have 
been documented in other clinical populations that were distinguishable from control 
groups by both methods (Morey et al., 2009; Tae et al., 2008). These studies are 
consistent with the present study in showing acceptable agreement between the two 
methods as demonstrated by Bland-Altman plots, yet the present study found 52% larger 
FS compared to MT volumes, with 35% more variance associated with FS than MT. 
Therefore, while the prior studies with clinical populations demonstrated that both MT 
and FS distinguished between symptomatic and asymptomatic individuals, the present 
study showed that neither method distinguished presymptomatic individuals. The present 
study, then, extends the findings of these earlier studies with symptomatic individuals by 
showing that while absolute volumes may differ between FS and MT, neither method 
may be able to reliably distinguish between eventual declining from stable individuals 
while they are in the presymptomatic stage, at least given the parameters of the present 
study.  
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This study was one of the few to compare FS and MT in presymptomatic 
individuals, and the inability to distinguish between eventual declining and stable 
participants here may suggest that the effect, if present is very small and difficult to 
reproduce. The current results are consistent with a recent study that found both FS and 
MT were able to correctly differentiate aMCI and AD participants from cognitively intact 
individuals, but found no differences between intact individuals who had cognitive 
complaints and intact individuals without complaints (Shen et al., 2010). The authors 
suggest that the cognitive complaints group may mimic a “preMCI” group, which may 
lend to the theory that those with impending cognitive decline may not show 
hippocampal volume differences compared to other cognitively intact individuals prior to 
measurable cognitive change. The Shen et al. study though is entirely cross-sectional; it is 
not known whether the participants with cognitive complaints eventually exhibited more 
cognitive decline over time than those without complaints. Thus, the present study builds 
upon their study by incorporating longitudinal follow-up. The lack of hippocampal 
volume difference in eventual declining and stable individuals suggests that such volume 
differences may not appear in the presymptomatic stage. It may be that measurable 
symptoms, whether cognitive and or behavioral, must be present to have associative 
detectable volume changes. 
The influence of APOE inheritance. 
 
 
Another explanation as to why group differences were not found in the present 
data may be related to the influence of the APOE allele on hippocampal volume. We 
have previously shown that the ability to predict cognitive decline at an 18-month follow-
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up assessment with a combination of structural and functional neuroimaging variables is 
enhanced when including APOE inheritance as a predictive variable (Hantke et al., 2013; 
Woodard et al., 2010). Unlike these previous prediction studies that aimed to predict 
decline with a number of variables, the goal of the present study was to directly compare 
two different methods of hippocampal volume measurement within the context of 
differentiating eventual stable and declining participants. Therefore, assessing the 
contribution of APOE in the present study was not the primary aim, but APOE was 
examined as it might influence the variables of interest. As such, a number of analyses 
incorporating APOE as an additional between subjects factor were conducted to explore 
the contribution of APOE in the present study. Indeed, a larger number of individuals in 
the Declining group had at least one copy of the ε4 allele (68%) compared to the Stable 
group (31%). This disproportional distribution of the ε4 allele is consistent with the 
reported risk of cognitive decline procured by the presence of even just one ε4 allele 
(Saunders et al., 1993).  
When entered into statistical analyses as an additional between subjects variable, 
a marginally significant interaction was found between Method, Side, Decline status and 
APOE with baseline hippocampal volumes. In particular, this marginally significant 
interaction suggested that ε4-negative Stable participants showed the laterality effect 
(right > left) when measured by both methods, and ε4-negative Declining participants (n 
=5) had larger left hippocampal volumes as measured by FS only. Additionally, ε4-
positive Stable participants (n = 14) had larger right compared to left volumes as 
measured by FS, but not MT, whereas ε4-positive Declining participants (n = 10) did not 
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differ.  Given the resulting small cell sizes in some subgroups, there was likely not 
sufficient power to fully detect differences, particularly with the relatively large amount 
variance of the smaller Declining group (SE = 88.62; as compared to the Stable group, 
SE = 52.10). Despite this, these data suggest that there likely is a valuable interaction 
with APOE, such that it may interact with the left and right hippocampi differently in 
presymptomatic individuals, and MT and FS may uniquely detect this interaction. To 
comprehensively explore this interaction, additional participants are needed to represent 
the differing subgroups, and as such, the present data would serve as a strong set of pilot 
data to infer future hypotheses. 
Because the present study was likely limited by small cell sizes, a number of 
hierarchical regressions were conducted to examine factors associated with cognition 
without the restrictions imposed by grouping variables. The present study found that 
baseline hippocampal volume and APOE could predict the change in RAVLT Delay 
performance from baseline to the 4.5-year follow-up, but not RAVLT 1-5 or DRS-2 Total 
performance. That is, FS left and right volumes and MT total volume both were 
marginally significant predictors of RAVLT Delay, but both models significantly 
benefitted from the addition of APOE. Therefore, it may be that at baseline, at least when 
participants are asymptomatic, APOE inheritance has a stronger influence on future 
cognitive outcome than hippocampal size alone. Therefore, to increase the ability to 
predict cognitive decline, hippocampal volume alone may not be sufficient, and other risk 
factors, such as APOE and perhaps other brain regions, may provide additive predictive 
ability. 
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The relationship between APOE inheritance and hippocampal volume has been 
well documented and explored given the connection with AD pathology, such as the beta 
amyloid accumulation. Molecular studies have shown that the ε4 allele has a stronger 
association with increased amounts of amyloid plaques relative to the ε2 and ε3 alleles 
(Mahley & Huang, 2012). The ε4 allele has also been implicated in affecting proper and 
sufficient clearance of beta amyloid, perhaps contributing to large accumulation in those 
individuals with AD (Bien-Ly, Gillespie, Walker, Yoon, & Huang, 2012).  Additionally, 
the ε4 allele is thought to be involved in alterations of synaptic activity, mitochondrial 
functioning, as well as the cytoskeletal structure and integrity of the cell (Mahley & 
Huang, 2012). Together, the strong relationship between APOE and hippocampal 
structure is expected. Indeed, ε4 carriers have been shown in some studies to have 
smaller hippocampal volumes and an excelled rate of atrophy relative to non-carriers (Jak 
et al., 2007; Schuff et al., 2009), perhaps due to the additive impact of these alterations in 
cell characteristics. Overall, APOE and in particular the ε4 allele, has been consistently 
shown to be a valuable indicator of change to the function and structure of the 
hippocampus. 
Together, these data suggest that APOE may have a strong and unique 
involvement in detecting future cognitive decline and may interact with the method used. 
This may suggest that hippocampal volume measurement, along with a combination of 
other factors, such as APOE inheritance, may provide the strongest predictive ability. 
Furthermore, although there were absolute volume differences between FS and MT, in 
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the present study, group differences were not detectable with either method. Therefore, 
within this context, MT was not found to afford any advantage over FS.  
Aim 2: Longitudinal Change in Hippocampal Volume by Group and Side  
 
 
To supplement the investigation of differences in baseline hippocampal volumes 
between future declining and stable individuals, the second aim was to investigate 
atrophy over time. More specifically, it was expected that the rate of hippocampal 
atrophy from the baseline to 4.5-year follow-up assessment, and at each time point, 
would differ between FS and MT, such that MT were expected to show a greater amount 
of atrophy between groups compared to FS.  
Atrophy measured longitudinally between groups.  
 
 
As expected, hippocampal volumes were smaller at the 18-month and 4.5-year 
follow-up assessments compared to the baseline assessment, demonstrating an overall 
trend of atrophy over time. Furthermore, there was a greater amount of atrophy occurring 
between the 18-month to 4.5-year follow-up assessment compared to the baseline to 18-
month follow-up. Additionally, the present study demonstrated an interaction between 
time and decline status, such that Declining and Stable participants showed a different 
rate of atrophy over time. Compared to Stable participants, Declining participants showed 
a more progressive pattern of atrophy over time, differing at each follow-up assessment, 
with a more dramatic reduction in hippocampal volume at the 4.5 year follow-up and an 
overall greater amount of atrophy than the Stable group. This more drastic change in 
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hippocampal volume reflects the decline in cognitive status at the 4.5-year assessment, 
suggesting that hippocampal volume is a useful indicator of cognitive decline.  
These data are consistent with the literature showing hippocampal atrophy occurs 
over time at a rate of about 1.18% per year as a result of healthy aging (Raz et al., 2004), 
and about twice that rate in AD (Jack et al., 1998). The rate of hippocampal atrophy has 
previously been shown to reliably predict conversion from MCI to AD (Henneman et al., 
2009; Visser et al., 2002). The results of the present study suggests that during an earlier 
stage of the disease process, when the individual is beginning to show mild cognitive 
symptoms, measurable hippocampal volume differences exist between the those who are 
declining and those who remain cognitively stable. 
The finding that declining participants show a more progressive rate of atrophy is 
consistent with an earlier study that conducted serial MRI measurements in controls, 
MCI, and AD over time (Jack et al., 2000). At the 3-year follow-up assessment, they 
found the declining groups to demonstrate a greater rate of hippocampal atrophy relative 
to those who remained stable (Jack et al., 2000). Notably, the present study defined 
decline by a memory measure (RAVLT) and general cognitive status (DRS-Total Score), 
whereas Jack et al. used the MMSE and CDR to determined cognitive status. The similar 
findings occurring in the context of different measures used to define decline, suggest 
that the RAVLT and DRS-Total score are adequate measures of cognitive decline, and 
that a pattern of more progressive atrophy occurring in declining individuals should be 
reproducible with reliable cognitive measures. Additionally, the present study further 
extends the findings in Jack et al. by including a third time point. That is, the present 
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study shows that not only do hippocampal volumes decrease over time, but that the 
amount of atrophy from the 18-month to 4.5 year follow-up is greater than the atrophy 
between baseline and the 18-month follow-up. This may suggest that the rate of atrophy 
becomes more progressive over time and is not necessarily linear. Yet, in the present 
study, the interval between the second and third scan was greater than the interval 
between the first and second scan, which may lead to a biased temporal gradient of 
hippocampal change over time. To account for the uneven intervals, an annual percent 
change of hippocampal volume was computed following the method of Jack et al. 2000. 
With this correction, the annual percent change of hippocampal volume of the Declining 
group was greater (1.60% per year) than the Stable group (.63% per year), but there was 
no annual difference between the two different intervals. That is, although the present 
data do not support a non-linear pattern of annual change, the data do support a greater 
rate of annual hippocampal atrophy in the Declining relative to the Stable participants. 
A differing pattern of atrophy between cognitively healthy individuals who 
eventually decline and those who remain stable has not always been found.  Kaye et al. 
(1997) followed cognitively healthy individuals over serial MRI measurements and 
showed that those who declined had a similar rate of atrophy than those who remained 
stable. One explanation for the inconsistent findings may be that the declining group had 
smaller volumes and were older to start out the study than the stable group, whereas in 
the present study groups were similar in age and hippocampal volume at baseline. That is, 
it may be that when volume differences are first emerging, the pattern of atrophy may be 
non-linear, and may stabilize over time as found in Kaye et al. Another possible 
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explanation for the differences between the two findings may be related to the differences 
in age of the samples. Participants were an average of 72 years old in the present study 
and 92 years in Kaye et al. Therefore, it is possible that “declining” group captured and 
followed in Kaye et al. was different than the “declining” group in the present study. That 
is, a disease process that is structurally but not yet cognitively measureable at 92 years 
old, is likely different from a neurodegenerative disease process that is structurally 
detectable at 72 years-old. Therefore, a different trajectory of atrophy in two potentially 
differently disease processes and cognitive groups is not surprising.  
FreeSurfer vs. manual tracing effects over time. 
 
 
In addition to finding that cognitively declining individuals demonstrate a more 
progressive rate of atrophy over time, the present study showed that FS measurements 
detected an overall greater amount of atrophy than MT over the 4.5-year study. Although 
not initially expected, one possibility is that this finding reflects the greater amount of 
variance associated with FS relative to MT. Indeed, over the 4.5-year study, the variance 
associated with FS was 53% larger than the variance associated with MT, which is 
greater than the 35% greater variance in FS found at baseline. A larger amount of 
variance associated with FS has been shown in previous cross-sectional studies (Morey et 
al., 2009). Together, these data may suggest that the error associated with FS increases 
over time. One explanation for this finding may be that the anatomical boundaries 
become more poorly differentiated during this atrophic process, causing FS to have 
increasing difficulty in discerning proper boundaries. Manual tracings may have less 
associated variance because this technique may benefit from a human perspective and 
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rational knowledge of adjacent anatomical structures in defining proper boundaries. Yet, 
another possibility is that MT may be too conservative in its definition of hippocampal 
tissue. Indeed, a qualitative review of one Declining and one Stable participant suggests 
that the two methods do not agree on boarder definition and perhaps in the more anterior 
portion of the hippocampus. If FS is quantifying atrophy of hippocampal tissue, in 
addition to adjacent regions that also may be losing tissue, then the overall amount of 
atrophy detected by FS would be greater than that detected by the more conservative MT. 
In that sense, the larger volumes produced by FS, may be leading to the greater amount of 
atrophy observed over time.  
Of course, it is also possible that FS may actually be a more sensitive technique in 
detecting atrophy over time and that MT may be too conservative of an approach. That is, 
the voxels included in FS and not MT quantification may be just as sensitive, if not more 
sensitive, in differentiating future cognitive decline. Thus, it is also possible that the 
larger volumes associated with FS is beneficial rather than detrimental. Indeed, in the 
present data, MT was not able to distinguish between future declining individuals. 
Therefore, it may be beneficial to trace the regions FS includes to determine if MT is also 
detecting change, in order to better understand why FS is showing greater atrophy over 
time than MT. This analysis may be beneficial for the continuing refinement of FS, and 
may lend to the further support of FS in large-scale research and potentially clinical 
settings. 
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Differences between groups over time. 
 
 
Despite greater associated error and consistently larger volumes, FS did not differ 
from MT in the ability to differentiate stable and declining individuals at each time point, 
or across intervals, which is inconsistent with what was anticipated. Individuals who 
declined were hypothesized to differ from those who were stable as measured by MT 
because of additional refinement, but not by FS because of the tendency to yield larger 
volumes. Furthermore, in contrast to expectation, Declining and Stable groups did not 
differ from one another at any time point. It is possible that group differences at each 
time point were not detected because the differences were not yet large enough to 
statistically detect. An interaction with method may not have been found because FS and 
MT similarly measured the pattern of hippocampal size in each group. That is, Declining 
participants may have had non-significantly smaller hippocampal volume than Stable 
participants, and FS volumes were larger than MT across groups, thus potentially 
washing out a significant interaction effect. An alternative explanation could be that 
structural differences did not exist between groups. Because the variance in the smaller 
Declining group was 73% greater than the variance in the Stable group, it was likely 
difficult to detect group differences with either method, even if they did exist. An 
examination for outliers revealed one person who was slightly under the 2 SD below the 
mean cut off score for manually traced volumes at the 4.5-year follow-up, but no other 
potential outliers were discovered. This suggests that there was not a strong influence of 
outliers contributing to the large amount of observed variance in the Declining group 
inhibiting the ability to detect group differences. 
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As with the first aim, because there were concerns related to power due to a small 
Declining group, hierarchical regressions were conducted to determine if hippocampal 
volume and APOE could predict cognitive scores. For both RAVLT 1-5 and DRS-2 
Total, adding APOE did not necessarily enhance the relationship, but APOE was 
beneficial when added to RAVLT Delay performance. In comparison to baseline 
hippocampal measurements, the 4.5-year volumes were more strongly related to 
cognitive performance, often even in the absence of APOE inheritance. Furthermore, 
even though there was a strong relationship at 4.5 years, baseline hippocampal volumes 
were more heavily dependent upon APOE and did not adequately predict this future 
pattern of cognitive performance. This may suggest that structural changes may occur in 
parallel to cognitive changes. 
Although group differences by method were not found, there were some notable 
strengths of the present study. In particular, the longitudinal study design within an aging 
population using a combination of cognitive and advanced neuroimaging procedures is 
relatively rare. Even within a longitudinal paradigm, the capability of assessing 
hippocampal volume at more than two time points is rare and is called for when possible 
(Henneman et al., 2009), because serial MRI and cognitive assessments allow for 
variations in how the data may be explored and understood. Additionally, the cognitive 
assessment in the present study is believed to capture a good representative sample of 
cognitive decline over time. Associating structural changes to cognitive change is of 
particular value, given that cognitive status is necessary to interpret the meaningfulness 
of structural changes (Jak et al., 2007). Relatedly, longitudinal approaches are of 
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statistical value in that each individual serves as his or her own control. The results of this 
study suggests that if detecting subtle group differences is the aim in lengthy longitudinal 
studies, MT may not provide reliable benefit beyond the more cost-effective FS. 
Limitations 
 
 
There also are several notable limitations to the present study that may have 
influenced the results and the subsequent conclusions. First, clearly power may have been 
a limitation of this study. Despite the power analysis and previous studies supporting the 
use of this sample size, the variance observed in the Declining group in particular, 
suggests that this study may have suffered from low power. Insufficient power increases 
the chances of failing to reject the null hypothesis when it is false. Specifically for this 
study, group differences were not observed between stable and declining participants 
across methods, but it is possible that differences were not observed because the sample 
size was too small and the variance was too great.  
Additionally, as mentioned in the methods section, test administration errors were 
made in which 10 participants were given the same version of the RAVLT at the 18-
month and the 4.5-year follow-up. This is a limitation due to the potential for practice 
effects and contamination of the groups. Data from these 10 participants were reviewed 
and two of the 10 participants met criteria for “Declining,” whereas the remaining eight 
participants met criteria for “Stable.” As proposed, all 10 participants were retained in 
analyses to maintain power. Some data have shown that elderly individuals given the 
same form yearly for three years demonstrate little practice effect (Mitrushina & Satz, 
1991). Yet, a previous analysis of this administration error indicated that those who 
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received the same form at the 18-month and 4.5- year follow-up within our larger sample 
of research participants benefited from practice effects for both RAVLT 1-5 and RAVLT 
Delay (unpublished data). As such, it is very possible that the eight individuals who were 
classified as “Stable” in this study may have benefited enough from practice effects to be 
classified as Stable, when they otherwise would have performed more consistent with our 
definition of “Decline.” This likelihood of group contamination could limit the ability to 
detect group effects.  
It may also be important to track which measures are detecting a decline in 
cognition. A qualitative review of the Declining group revealed two out of the 15 
participants showed a clear decline, by declining on all three outcome measures. Four out 
of 15 declined on two outcome measures, and the remaining nine participants declined on 
one measure. Additionally, nine participants declined on the RAVLT Delay, eight on the 
RAVLT 1-5, and six on the DRS-2. Together, these data suggest that the current 
Declining group may be comprised of individuals who experienced only a subtle 
reduction in cognitive performance, and that the RAVLT may be a slightly more sensitive 
measure to this subtle decline. It may be that more group differences would be reliably 
detected if there were more individuals in the Declining group that experienced a more 
drastic decline.  
Although the change in cognitive performance is a measurable and meaningful 
amount of decline, it is important to note that the reduction, for the majority in the group, 
is subtle and may not represent a large change in functional status. That is, in a clinical 
setting, the subtle change detected in about 10 of the participants in the Declining group 
77 
 
may result in a caution to follow-up to monitor for further cognitive change, but perhaps 
no clinical diagnosis. However, the more drastic decline detected in the two participants 
who declined on all three measures, may warrant a closer assessment of possible 
accompanying functional decline and consideration of clinical diagnosis. Although there 
is no reliable treatment for a neurodegenerative process, there are some medications that 
have shown some benefit of slowing progression of cognitive decline for some 
individuals (Dantoine et al., 2006; Kozauer & Katz, 2013; Tariot et al., 2001). If 
biomarkers were able to reliably detect future cognitive decline, it may be useful to 
consider a trial of the available medications to assess individual response to treatment. As 
more targets for intervention become available, perhaps more reliable and effective 
interventions may be generated to offer to those at risk for or at the early stages of 
cognitive decline. 
Another measurement consideration is that way in which cognition was assessed 
in the present study to define cognitive status. In the present study, a verbal learning task 
(RAVLT) and screen of several cognitive domains (DRS-2) were used to assess 
cognition. It is possible that only using these measures resulted in an incomplete 
cognitive assessment, such that some individuals may have declined in a manner or 
cognitive domain that was not thoroughly assessed. It is possible, then, that some 
individuals who experienced a decline in cognition over the 4.5-year interval remained in 
the Stable instead of Declining group. While a more comprehensive neuropsychological 
assessment may have been beneficial in some respects, using these measures and this 
definition of decline, we have previously shown group differences in cognitively intact 
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individuals who eventually decline compared to those who remain stable (Hantke et al., 
2013; Woodard et al., 2010). 
Another potential limitation is the use of FS as a mask on which the manual 
tracings were edited. That is, it is possible that beginning with an automated FS mask 
may have introduced the potential for inherent bias in manual tracings. However, this 
concern was addressed in the following ways. First, the mask offered a starting point, 
wherein voxels were both subtracted and added as needed to adequately cover 
hippocampal tissue. Some form of automated method to help isolate the hippocampus is 
typical as a starting point for any manual tracing approach. Second, beginning with a 
mask generated by FS likely introduced the same amount of bias as any other automated 
method would have introduced. More, if an alternative method were used for this 
purpose, analyses would have been needed to determine its effects on the results. Because 
the goal of this study was to determine whether FS or manual tracing was better able to 
distinguish future and gradual cognitive decline, comparing unedited FS measurements 
with manual tracings that were edits of FS seemed the most parsimonious approach. 
Importantly, all raters were blinded to session number, participant number, genetic risk 
status, and neuropsychological testing performance to prevent biases in tracings 
introduced by the raters. This method of manual hippocampal measurement has been 
used and accepted in previous publications (Hantke et al., 2013; Woodard et al., 2010). 
Future Directions 
 
 
The results of the present study provide a framework from which additional 
research may build upon in further investigation of useful biomarkers of AD. The present 
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study used archival data to test out the presented hypotheses. Since this study, additional 
participants have undergone the 4.5-year follow-up scan and neuropsychological 
assessment. A necessary and logical follow-up study would be to use the additional 
participants that have been collected to comprehensively explore this potential interaction 
between FS and MT hippocampal volume measurement and cognitive decline, along with 
APOE ε4 inheritance, to determine if this type of structural analysis may be a useful 
indicator of future cognitive decline. In particular, there were indications that a valuable 
4-way interaction between Method, Side, Decline, and APOE at baseline may emerge as 
significant if additional power was procured to test out this interaction. Additionally, the 
individuals that were administered the repeat RAVLT form should be re-evaluated to 
obtain a more accurate representation of their current cognitive functioning. Indeed, the 
participants that were administered the incorrect RAVLT form at the 4.5-year follow-up 
are projected to return for a repeat assessment of memory function that will ideally clarify 
the Stable and Declining groups.	  
The present study suggests that detecting future cognitive decline, and particularly 
attempting to capture the neuropathology of AD at an early stage, is complex and may 
require cross-sectional and longitudinal paradigms, as well as a combination of 
indicators. That is, the present data suggest that APOE may be useful in increasing the 
ability to detect future cognitive decline, and it may be important to explore the additive 
benefit of incorporating additional memory facilitating brain regions in future volumetric 
studies. In particular, the function and structure of the posterior cingulate (Protas et al., 
2013), as well as the caudate and thalamus (Ryan et al., 2013), have been recently 
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identified as regions that may be involved in the early stages of AD. Future studies 
should consider combining the impact of changes in these regions, which may help to 
improve the ability to distinguish future decline and perhaps eventually predict AD.	  
General Conclusion 
 
 
 The present study sought to compare two commonly used hippocampal 
segmentation techniques in a structural analysis of distinguishing between future 
declining from stable individuals in a sample of cognitively healthy elders. The scope of 
the present study is in line with the recent call for further exploration of predictive factors 
in individuals who later develop Alzheimer’s disease (Albert et al., 2011; Sperling et al., 
2011). Hippocampal volume has been raised as a potential factor in predicting decline, 
even in presymptomatic elders (Woodard et al., 2010).  
Taken together, the present study did not find detectable baseline hippocampal 
volume differences in asymptomatic individuals who later exhibit cognitive decline. 
However, over time, Declining participants did show a more progressive amount of 
atrophy, and this pattern was detectable by FS and MT alike. These data speak to the 
usefulness of combining static measurements with the longitudinal measurements, 
because the overall pattern may be more meaningful. That is, although Declining 
participants did not have smaller hippocampal volumes at any time point, as was 
hypothesized, they did show an overall more progressive rate of atrophy over time. 
Furthermore, although FS was consistently shown to produce larger volumes than MT, 
there were no statistical differences between MT and FS in the ability to distinguish 
decline status. Therefore, because MT is vastly more time consuming and less practical, 
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and although FS produced larger volumes than MT, MT may not be more beneficial than 
FS in detecting hippocampal atrophy over time. Future studies with a larger sample are 
needed to more comprehensively explore the impact of APOE status in hippocampal 
measurement and cognitive decline over time.  A tool that allows for rapid and reliable 
hippocampal measurement would serve to benefit ongoing research efforts in the quest to 
predict Alzheimer’s disease, and potentially confer a degree of clinical utility. 
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Table 1   
Participant Characteristics and Neuropsychological Performance at Baseline.   
 
 
Stable 
(n = 45)  
Declining 
(n = 15)   
Variables Mean SD  Mean SD p η2 
Demographics         
Age (yrs) 71.29 4.50  72.53 4.41 .36 .01 
Education (yrs) 15.11 2.71  14.20 2.18 .24 .02 
       rφ 
Sex 12M, 33F --  3M, 12F -- .74 .07 
Family History 22FH+, 23FH- --  
10FH+, 
5FH-  -- .37 .23 
APOE inheritance 14ε4+, 31ε4- --  
10ε4+, 
5ε4- -- .03 .31 
Neuropsychological 
Testing       
 
η2 
DRS-2 Total 141.13 2.17  139.47 4.44 .18 .06 
RAVLT Trials 1-5 50.31 8.10  48.13 8.72 .38 .01 
RAVLT DR 10.16 2.57  9.33 2.79 .30 .02 
        
 
Note. All indices represent raw scores. M = male; F = female; FH = Family History; FH- 
= no family history, FH+ = positive family history; APOE = Apolipoprotein-E ε4 
inheritance; ε4+ = at least one ε4 allele; ε4 - = no ε4 allele; DRS-2= Mattis Dementia 
Rating Scale-2; RAVLT = Rey Auditory Verbal Learning Test; DR = Delayed Recall. 
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Table 2   
Neuropsychological Performance at the 4.5-year Follow-up Assessment.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Note. All indices represent raw scores. DRS-2= Mattis Dementia Rating Scale, Second 
Ed; RAVLT = Rey Auditory Verbal Learning Test; DR = Delayed Recall. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stable 
(n = 45)  
Declining 
(n = 15)   
Neuropsychological 
Testing Mean SD  Mean SD p η
2 
        
DRS-2 Total 141.49 2.27  136.67 6.00 .019 .22 
RAVLT Trials 1-5 51.00 7.53  40.87 11.36 .005 .21 
RAVLT DR 10.58 2.37  6.00 4.24 .001 .32 
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Table 3 
 
Hierarchical Multiple Regression with Baseline Hippocampal Volumes and APOE 
Predicting Residualized Change Scores for RAVLT 1-5.  
 
 R R2 R2 
Change 
B SE β p 
Model 1        
Step 1 .157 .025      
FS Total     < .001 < .001 .157 .231 
Step 2 .203 .041 .017     
FS Total     < .001 < .001 .156 .233 
APOE    -.258 .260 -.129 .326 
Model 2        
Step 1 .160 .026      
FS Left    < .001 < .001 .129 .578 
FS Right    < .001 .001 .036 .878 
Step 2 .220 .048 .023     
FS Left     .001 .001 .230 .354 
FS Right    < .001  .001 -.065 .793 
APOE    -.325 .282 -.162 .253 
Model 3        
Step 1 .177 .031      
MT Total     < .001 < .001 .177 .175 
Step 2 .209 .044 .012     
MT Total     < .001 < .001 .165 .210 
APOE    -.233 .262 -.111 .396 
Model 4        
Step 1 .248 .061      
MT Left     .001 .001 .428 .105 
MT Right    - .001  .001 -.243 .355 
Step 2 .276 .076 .015     
MT Left      .001  .001 .435 .101 
MT Right    - .001  .001 -.263 .318 
APOE    -.244 .260 -.122 .351 
Note. Statistical significance: *p < .05; ** p < .01; FS Total = FreeSurfer total 
hippocampal volume collapsed across side; FS Left = FreeSurfer left hippocampus; FS 
Right = FreeSurfer right hippocampus; MT Total = manual tracing total hippocampal 
volume collapsed across side; MT Left = Manual tracings left hippocampus; MT Right = 
Manual tracing right hippocampus; R2 = amount of variance explained by IVs; R2 Change 
= additional variance in DV; B = Unstandardized coefficient; β = Standardized 
coefficient; SE = Standard Error. 
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Table 4  
 
Hierarchical Multiple Regression with Baseline Hippocampal Volumes and APOE 
Predicting Residualized Change Scores for RAVLT Delay.  
 
 R R2 R2 
Change 
B SE β p 
Model 1        
Step 1 .223 .050      
FS Total     < .001 < .001 .223 .087 
Step 2 .448 .200** .151**     
FS Total     < .001 < .001 .221 .067 
APOE    -.779 .238 -.388 .002 
Model 2        
Step 1 .313 .098      
FS Left    - .001  .001 -.263 .241 
FS Right     .001 < .001 .492 .031 
Step 2 .455 .207** .109**     
FS Left     < .001  .001 -.041 .854 
FS Right     .001  .001 .271 .232 
APOE    -.713 .257 -.355 .007 
Model 3        
Step 1 .242 .059      
MT Total     < .001 < .001 .242 .062 
Step 2 .438 .192** .133**     
MT Total     < .001 < .001 .202 .097 
APOE    -.737 .240 -.367 .003 
Model 4        
Step 1 .253 .064      
MT Left    < .001 .001 -.023 .930 
MT Right     .001 .001 .273 .298 
Step 2 .441 .195** .131**     
MT Left     < .001  .001 -.002 .994 
MT Right     .001 .001 .211 .392 
APOE    -.731 .243 -.364 .004 
Note. Statistical significance: *p < .05; ** p < .01; FS Total = FreeSurfer total 
hippocampal volume collapsed across side; FS Left = FreeSurfer left hippocampus; FS 
Right = FreeSurfer right hippocampus; MT Total = manual tracing total hippocampal 
volume collapsed across side; MT Left = Manual tracings left hippocampus; MT Right = 
Manual tracing right hippocampus; R2 = amount of variance explained by IVs; R2 Change 
= additional variance in DV; B = Unstandardized coefficient; β = Standardized 
coefficient; SE = Standard Error. 
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Table 5  
 
Hierarchical Multiple Regression with Baseline Hippocampal Volumes and APOE 
Predicting Residualized Change Scores for DRS-2 Total.  
 
 R R2 R2 
Change 
B SE β p 
Model 1        
Step 1 .235 .055      
FS Total     < .001 < .001 .235 .071 
Step 2 .282 .080 .025     
FS Total     < .001 < .001 .234 .071 
APOE    -.315 .255 -.157 .222 
Model 2        
Step 1 .248 .062      
FS Left     .001 .001 .253 .268 
FS Right    < .001 .001 -.006 .980 
Step 2 .320 .102 .040     
FS Left     .001 .001 .388 .110 
FS Right    < .001  .001 -.140 .561 
APOE    -.434 .273 -.216 .118 
Model 3        
Step 1 .140 .020      
MT Total     < .001 < .001 .140 .287 
Step 2 .200 .040 .021     
MT Total     < .001 < .001 .124 .346 
APOE    -.290 .262 -.145 .273 
Model 4        
Step 1 .140 .020      
MT Left    < .001 .001 .058 .827 
MT Right    < .001 .001 .086 .747 
Step 2 .201 .040 .021     
MT Left     < .001 .001 .067 .803 
MT Right    < .001 .001 .062 .818 
APOE    -.291 .265 -.145 .277 
Note. Statistical significance: *p < .05; ** p < .01; FS Total = FreeSurfer total 
hippocampal volume collapsed across side; FS Left = FreeSurfer left hippocampus; FS 
Right = FreeSurfer right hippocampus; MT Total = manual tracing total hippocampal 
volume collapsed across side; MT Left = Manual tracings left hippocampus; MT Right = 
Manual tracing right hippocampus; R2 = amount of variance explained by IVs; R2 Change 
= additional variance in DV; B = Unstandardized coefficient; β = Standardized 
coefficient; SE = Standard Error. 
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Table 6  
 
Areas Under the ROC Curve for Baseline and 4.5-year Hippocampal Volumes 
 
 FreeSurfer AUC p Manual Tracing AUC p 
Baseline     
Left .505 .952 .446 .533 
Right .437 .468 .455 .603 
Total .476 .778 .430 .417 
4.5 Years     
Left .439 .479 .372 .140 
Right .348 .080 .366 .122 
Total .396 .084 .354 .077 
Note. AUC values indicate areas under the ROC (receiver operating characteristic) curve. 
Statistical significance: *p < .05. 
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Table 7  
 
Correlations of 4.5-year Follow-up Hippocampal Volumes and Cognitive Measures 
  
 RAVLT 1-5 RAVLT Delay  DRS-2 Total APOE  
FreeSurfer     
Left Hipp 
 
r =.271 
p = .036 
r =.229 
p = .078 
r =.430 
p = .001 
p = .631 
Right Hipp 
 
r =.305 
p = .018 
r =.326 
p = .011 
r =.425 
p = .001 
p = .168 
FS Total Hipp 
 
r =.302 
p = .019 
r =.292 
p = .024 
r =.448 
p < .001 
p = .328 
Manual Tracings     
Left Hipp 
 
r =.318 
p = .013 
r =.262 
p = .043 
r =.426 
p = .001 
p = .401 
Right Hipp 
 
r =.323 
p = .012 
r =.335 
p = .009 
r =.330 
p = .010 
p = .105 
 MT Total Hipp 
 
r =.332 
p = .010 
r =.310 
p = .016 
r =.390 
p = .002 
p = .200 
 APOE Status     
ε4 Negative 50.0 (6.8) 10.5 (2.5) 141.0 (2.8)  
ε4 Positive 46.2 (12.5) 
p = .188 
7.8 (4.2) 
p = .009 
139.3 (6.1) 
p = .204 
 
Note. Left Hipp = Left Hippocampus; Right Hipp = Right Hippocampus; Total Hipp = 
right and left hippocampal volumes combined; RAVLT 1-5 = Rey Auditory Verbal 
Learning Test Trials 1-5 raw score; RAVLT Delay = Rey Auditory Verbal Learning Test 
Delay Recall raw score; DRS-2 Total = Dementia Rating Scale -2 Total Score; APOE 
Status = ApolipoProtein E 4 positive of negative; r = Pearson Correlation; p = alpha level 
set at 0.05 for 2-tailed. APOE Status values indicate Mean (Standard Deviation).  
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Table 8 
 
Hierarchical Multiple Regression with 4.5-Year Hippocampal Volumes and APOE 
Predicting Residualized Change Scores for RAVLT 1-5  
  
 R R2 R2 
Change 
B SE β p 
Model 1        
Step 1 .267 .071*      
FS Total     < .001 < .001 .267 .039 
Step 2 .284 .081 .009     
FS Total     < .001 < .001 .255 .051 
APOE    -.194 .257 0.097 .453 
Model 2        
Step 1 .280 .079      
FS Left    .001 < .001 .280 .213 
FS Right    < .001 < .001 < .001 .998 
Step 2 .303 .092 .043     
FS Left     .001 < .001 .311 .173 
FS Right    < .001 < .001 -.046 .841 
APOE    -.237 .263 -.118 .371 
Model 3        
Step 1 .315 .099*      
MT Total     < .001 < .001 .315 .014 
Step 2 .324 .105* .006     
MT Total     < .001 < .001 .301 .021 
APOE    -.158 .255 -.079 .538 
Model 4        
Step 1 .330 .109*      
MT Left    .001 .001 .351 .166 
MT Right    < .001 .001 -.025 .921 
Step 2 .345 .119 .010     
MT Left     .001 .001 .381 .139 
MT Right    < .001 .001 -.072 .780 
APOE    -.206 .260 -.103 .432 
Note. Statistical significance: *p < .05; ** p < .01; FS Total = FreeSurfer total 
hippocampal volume collapsed across side; FS Left = FreeSurfer left hippocampus; FS 
Right = FreeSurfer right hippocampus; MT Total = manual tracing total hippocampal 
volume collapsed across side; MT Left = Manual tracings left hippocampus; MT Right = 
Manual tracing right hippocampus; R2 = amount of variance explained by IVs; R2 Change 
= additional variance in DV; B = Unstandardized coefficient; β = Standardized 
coefficient; SE = Standard Error. 
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Table 9 
 
Hierarchical Multiple Regression with 4.5-Year Hippocampal Volumes and APOE 
Predicting Residualized Change Scores for RAVLT Delay  
 
 R R2 R2 
Change 
B SE β p 
Model 1        
Step 1 .285 .081*      
FS Total     < .001 < .001 .285 .027 
Step 2 .456 .208** .127**     
FS Total     < .001 < .001 .239 .050 
APOE    -.720 .239 -.359 .004 
Model 2        
Step 1 .308 .095      
FS Left    < .001 < .001 -.050 .820 
FS Right    .001 < .001 .348 .119 
Step 2 .458 .210** .115**     
FS Left     < .001 < .001 .040 .850 
FS Right    < .001 < .001 .211 .326 
APOE    -.700 .245 -.349 .006 
Model 3        
Step 1 .252 .063      
MT Total     < .001 < .001 .252 .052 
Step 2 .433 .187** .124**     
MT Total     < .001 < .001 .192 .119 
APOE    -.717 .243 -.357 .005 
Model 4        
Step 1 .289 .084      
MT Left    < .001 .001 -.148 .561 
MT Right    .001 .001 .408 .113 
Step 2 .439 .193** .109**     
MT Left     < .001 .001 -.049 .841 
MT Right    .001 .001 .250 .316 
APOE    -.687 .249 -.342 .008 
Note. Statistical significance: *p < .05; ** p < .01; FS Total = FreeSurfer total 
hippocampal volume collapsed across side; FS Left = FreeSurfer left hippocampus; FS 
Right = FreeSurfer right hippocampus; MT Total = manual tracing total hippocampal 
volume collapsed across side; MT Left = Manual tracings left hippocampus; MT Right = 
Manual tracing right hippocampus; R2 = amount of variance explained by IVs; R2 Change 
= additional variance in DV; B = Unstandardized coefficient; β = Standardized 
coefficient; SE = Standard Error. 
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Table 10 
 
Hierarchical Multiple Regression with 4.5-Year Hippocampal Volumes and APOE 
Predicting Residualized Change Scores for DRS-2 Total.  
 
 R R2 R2 
Change 
B SE β p 
Model 1        
Step 1 .341 .116**      
FS Total     < .001 < .001 .341 .008 
Step 2 .260 .130** .013     
FS Total     < .001 < .001 .326 .011 
APOE    -.233 .250 -.116 .355 
Model 2        
Step 1 .356 .127*      
FS Left    .001 < .001 .346 .116 
FS Right    < .001 < .001 .012 .954 
Step 2 .382 .146* .019     
FS Left     .001 < .001 .382 .085 
FS Right    < .001 < .001 -.043 .846 
APOE    -.285 .255 -.142 .269 
Model 3        
Step 1 .261 .068*      
MT Total     < .001 < .001 .261 .044 
Step 2 .285 .081 .013     
MT Total     < .001 < .001 .241 .067 
APOE    -.236 .258 -.118 .364 
Model 4        
Step 1 .346 .120*      
MT Left    .002 .001 .573 .025 
MT Right    -.001 .001 -.302 .230 
Step 2 .383 .147* .027     
MT Left     .002 .001 .622 .016 
MT Right    -.001 .001 -.380 .140 
APOE    -.341 .256 -.170 .189 
Note. Statistical significance: *p < .05; ** p < .01; FS Total = FreeSurfer total 
hippocampal volume collapsed across side; FS Left = FreeSurfer left hippocampus; FS 
Right = FreeSurfer right hippocampus; MT Total = manual tracing total hippocampal 
volume collapsed across side; MT Left = Manual tracings left hippocampus; MT Right = 
Manual tracing right hippocampus; R2 = amount of variance explained by IVs; R2 Change 
= additional variance in DV; B = Unstandardized coefficient; β = Standardized 
coefficient; SE = Standard Error. 
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Figure 1. Intraclass correlation (ICC) plots for manual hippocampal volume 
measurements. Intraclass correlations were strong for Alternate Rater 1 (A) and Alternate 
Rater 2 (B), as was intra-rater reliability (C).  The average volume of the alternate rater is 
shown as the reference line for the X-axis, and the average volume of the primary rater is 
shown as the reference line for the y-axis. 
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Figure 2. Separate hippocampal volume comparisons by method and group. FreeSurfer 
produced significantly larger estimates of baseline hippocampal volume than did manual 
tracing. Collapsed across methods, there was no significant baseline volume difference 
between Stable and Declining Participants. Error bars represent SEM. 
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Figure 3. Comparison of left and right baseline hippocampal volume. Collapsed across 
methods and group, right baseline hippocampal volumes were significantly larger than 
left baseline hippocampal volumes. Error bars represent SEM. 
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Figure 4. Baseline hippocampal volume comparison of method by side. FreeSurfer 
produced significantly larger left and right baseline hippocampal volumes compared to 
manual tracings. For each method, right hippocampal volumes were larger than left 
volumes. Error bars represent SEM. 
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Figure 5. Baseline hippocampal volume comparison of method by group. Stable and 
Declining participants did not have significantly different baseline hippocampal volumes 
as measured by FreeSurfer or manual tracing. Error bars represent SEM. 
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Figure 6. Baseline hippocampal volume comparison of group by side. Left and right 
hippocampal volumes did not differ significantly between Stable and Declining 
participants.  Error bars represent SEM. 
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Figure 7. Baseline hippocampal volume comparison of method by side by group. 
Bilaterally, baseline hippocampal volumes measured by FreeSurfer and manual tracing 
not differ significantly between Stable and Declining participants. Error bars represent 
SEM. 
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Figure 8. Bland-Altman plot for baseline left hippocampal volumes. The vast majority of 
left hippocampal measurements between FreeSurfer and manual tracings fall within two 
standard deviations of the difference mean, or within the expected range.  
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Figure 9. Bland-Altman plot for baseline right hippocampal volumes. The vast majority 
of right hippocampal measurements between FreeSurfer and manual tracings fall within 
two standard deviations of the difference mean, or within the expected range.  
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Figure 10. Bland-Altman plot for baseline total hippocampal volumes. The vast majority 
of left hippocampal measurements between FreeSurfer and manual tracings fall within 
two standard deviations of the difference mean, or within the expected range.  
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Figure 11. Baseline hippocampal volumes comparisons of method by side by APOE. 
ε4-negative participants had larger right than left hippocampal volumes as measured by 
both FreeSurfer (FS) and manual tracings (MT). Yet, ε4-positive participants had larger 
right than left hippocampal volumes measured by FS, but not by MT. Error bars represent 
SEM. 
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Figure 12. Comparison of baseline hippocampal volume of method by side by decline 
status by APOE. Stable ε4-negative and ε4 –positive participants had greater left 
compared to right hippocampal volumes, as measured by both FreeSurfer (FS) and 
manual tracings (MT). This pattern was found in ε4-negative Declining participants with 
FS, but not MT. Declining ε4-positive participants did not differ between side for either 
method. Error bars represent SEM. 
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Figure 13. Baseline hippocampal volume comparison of method by decline status by 
APOE for the left and right hippocampus separately. FreeSurfer volumes were greater 
than manually traced volumes. ε4-positive participants did not differ from ε4-negative 
participants. There was not a significant between declining and stable participants. Error 
bars represent SEM. 
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Figure 14. Receiver operating characteristic (ROC) curve for baseline hippocampal 
volumes. Baseline hippocampal volumes measured by FreeSurfer (FS) and manual 
tracings (MT) were not able to significantly classify cognitive decline.  
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Figure 15. Sagittal and coronal FreeSurfer and manual tracing in one Stable participant. 
Panel 1a = Sagittal SPGR of hippocampus; Panel 1b = Sagittal overlap of FreeSurfer (FS) 
and manual tracing (MT). Panel 2a = Coronal SPGR of hippocampus; Panel 2b = Sagittal 
overlap of FS and MT. Blue = tissue uniquely identified by FS; red = tissue uniquely 
identified by MT; yellow = overlap between FS and MT. FreeSurfer yielded overall 
larger volumes than MT. 
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Figure 16. Sagittal and coronal FreeSurfer and manual tracing in one Declining 
participant. Panel 1a = Sagittal SPGR of hippocampus; Panel 1b = Sagittal overlap of 
FreeSurfer (FS) and manual tracing (MT). Panel 2a = Coronal SPGR of hippocampus; 
Panel 2b = Sagittal overlap of FS and MT. Blue = tissue uniquely identified by FS; red = 
tissue uniquely identified by MT; yellow = overlap between FS and MT. FreeSurfer 
yielded overall larger volumes than MT. 
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Figure 17. Comparison of hippocampal volume at each time point. Hippocampal 
volumes significantly reduced over time. Error bars represent SEM. 
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Figure 18. Comparison of total hippocampal volume by method. Collapsed across all 
time points, FreeSurfer produced significantly larger hippocampal volumes than manual 
tracings. Error bars represent SEM. 
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Figure 19. Comparison of total hippocampal volume by group. Collapsed across all three 
time points, hippocampal volumes did not differ between Stable and Declining 
participants. Error bars represent SEM. 
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Figure 20. Comparison of hippocampal volumes across time by group. The hippocampal 
volume of Stable participants did not differ from baseline to the 18-month follow-up, but 
were significantly smaller at the 4.5-year follow up compared to baseline. Declining 
participants had significantly smaller hippocampal volumes at each successive time point. 
Error bars represent SEM. 
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Figure 21. Comparison of hippocampal volumes over time by group and method. 
Collapsed across time, FreeSurfer and manually traced hippocampal volumes did not 
differ between Stable and Declining participants. Error bars represent SEM. 
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Figure 22. Comparison of hippocampal volumes across time by method. FreeSurfer and 
manually traced hippocampal volumes did not differ significantly across time points. 
Error bars represent SEM. 
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Figure 23. Hippocampal volume comparison across time by method and group. Manually 
traced and FreeSurfer hippocampal volumes did not differ significantly between Stable 
and Declining participants at each time point. Error bars represent SEM. 
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Figure 24. Comparison of hippocampal volume over time by APOE for FreeSurfer and 
manual tracings separately. When measured with FreeSurfer (FS), ε4-positive 
participants had smaller volumes at the 4.5-year compared to the 18-month assessment, 
but did not differ from the 18-month compared to baseline assessment. ε4-positive 
participants showed marginally smaller 18-month compared to baseline volumes, and 
significantly smaller 4.5-year compared to 18-month volumes. This pattern was not found 
in manual tracings, which yielded no significant differences. Error bars represent SEM. 
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Figure 25. Three separate comparisons of hippocampal volume of method by group for 
each change interval. There were no significant differences between the amount of 
change in hippocampal volume between Stable and Declining individuals at any interval. 
The amount of change from baseline to 4.5 year volumes as measured by FreeSurfer was 
marginally greater in Declining compared to Stable participants. Data are presented as 
absolute values, such that higher values indicate greater atrophy. Error bars represent 
SEM. 
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